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ABSTRACT 
 
 
BACKGROUND: 
 
Human Papillomavirus (HPV) is the most common sexually-transmitted agent. Infections with 
oncogenic HPV types 16 & 18 are causally linked to the development of cervical cancer, as well 
as a proportion of anal, oropharyngeal, vulvar, vaginal and penile cancers and their associated 
precancerous lesions. Immune suppression increases the likelihood of HPV-related diseases, and 
people with human immunodeficiency viral (HIV) infection or with HIV-positive partners are at 
a higher risk of precancerous lesions and cancers, as well as genital warts.  
OBJECTIVES: 
Determine the prevalence and distribution of high risk (HR) oncogenic HPV genotypes in HIV-
positive adults in Atlantic Canada. Examine association between HR HPV genotypes and 
premalignant lesions and incident malignancy; Examine association between premalignant 
lesions and malignancy and patients’ demographics and underlying risk factors. 
METHODS: 
This prospective cohort study was designed for four years in Atlantic Canada HIV care clinics.  
Total 300 were enrolled in the study and of them, 263 were included in the final analysis. 
Participants were required to complete a confidential questionnaire to obtain demographic and 
risk factor data. Annual collection of oropharyngeal and anal swab specimens from all 
participants and an additional cervical specimen from females were obtained. All specimens 
were tested for cytologic abnormalities, HPV DNA and HPV genotyping. The ASIR of the 
incident cancers was calculated using the Canadian general population as reference. 
RESULTS:  
Of 263 patients 93.2% were males. The mean (SD) age of the study population at the enrollment 
time was 46.9 (9.4) years and 51.3 (9.1) years at the study’s end. A total of 227 (86.3%) 
participants were positive for HPV infection. Of these, 88.1% had HPV infection at one body site 
and 11.9% had HPV genotypes detected at two body sites simultaneously. Up to 50 HPV 
genotypes were detected, of which 32 (63%) were HR oncogenic types.                                                                                                                                   
Eight (16%) HPV types were significantly associated with the confirmed 31 (11.8%) cases of 
precancerous lesions and 8 (3.3%) incident cases of malignancy. The precancerous lesions  
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significantly associated with patients CD4 cell count < 200 cells/mL (p=0.034), smoking 
(p=0.007), history of anogenital warts (p=0.002) and genital herpes (p=0.007).                         
CONCLUSIONS:  
The overall incidence of cancer was 3.3%, all of them diagnosed in males. The ASIR (95%CI) of 
anal cancer is 535/100,000 (30-970) and ASIR (95%CI) of oral cancer is 533/100,000 (30-970).                                                                                                                    
 
KEY WORDS:  
Human papillomavirus infection, anal cancer, cervical cancer, head and neck cancer, squamous 
cell carcinoma, HPV genotyping, HPV prevalence and incidence, HPV and malignancy, HPV 
risk factors, HIV-HPV co-infection, prevalence of cancer in MSM. 
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CHAPTER 1 
 
INTRODUCTION 
1.1 Introduction to the Thesis 
Human Papillomavirus (HPV) infection is believed to be one of the most common sexually 
transmitted infections (STI) in Canada and around the world. 
The Centre for Disease Control (CDC) estimates that at least half of all sexually active 
individuals will acquire HPV at some point in their lives (CDC Fact Sheet, 2011); however this 
viral infection usually clears by itself and causes no signs or symptoms. 
The greatest risk factors for infection with HPV in the general population are young age 
and sexual activity. Besides these factors, other risk factors for HPV infection and clinical 
sequelae of infection include high number of sexual partners, smoking, and co-infection with 
Chlamydia trachomatis and/or Herpes Simplex Virus (HSV2) which is also called Human 
Herpesvirus 2 (HHV-2) (Canadian Cancer Society (CCS), Risk Factors for Cervical Cancer, 
2015). HPV transmission occurs directly through genital-to-genital, orogenital, and anogenital 
contact, and infrequently through hand-to-genital contact (Ryan DP et al, 2000). HPV can also 
be contracted through vertical (from mother to child) and fomite (via inanimate objects such as 
sex toys) transmission (Mayeaux EJ Jr & Spigener SD, 1997). Condoms do not prevent 
transmission since HPV may infect the base of the penis or the upper thigh areas not covered by 
condoms (Goldstone S, 1999). The incubation period of HPV is usually 6 weeks to 8 months, but 
can be as long as several years. Most HPV infections are subclinical; hence asymptomatic men 
may act as an HPV reservoir because the virus can live in latent form in the urethra or prostate 
gland (Frega A et al, 2013).                                                                                                                       
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While HPV infection is mostly transient in the majority of individuals and does not lead to 
disease, immune suppression increases the risk of HPV (CCS, 2015).                                           
Those with human immunodeficiency viral (HIV) infection or with HIV-positive partners are at 
a higher risk of precancerous lesions and cancers as well as genital warts (Kreuter A. and 
Wieland U., 2009). Furthermore, for those who have HIV infection, there is a heightened risk of 
rarer and/or more aggressive forms of cancer which tend to be more advanced, occurring in 
younger age with poorer prognosis. They are also more likely to spread to unusual sites (Jensen 
et al., 2007; Lillo & Uberti-Foppa, 2006; Nicol et al., 2005; Palefsky et al., 1999; Schlecht et al., 
2005). 
                                                                                                                                                          
1.2 Epidemiology of HIV-HPV Co-Infection 
Transmission of HPV infection occurs primarily by skin-to-skin sexual contact and HPV is 
prevalent in all sexually active populations. Epidemiologic studies indicated that the risk of 
contracting HPV infection in the general population is influenced by: sexual activity itself; 
sexual activity at an early age; multiple sexual partners at any time of life, or being the partner of 
someone who had multiple sexual partners; and personal history of other sexually transmitted 
diseases. The primary immune response to HPV infection is cell-mediated; therefore, conditions 
that impair cell-mediated immunity such as human immunodeficiency viral disease (HIV) should 
increase the risk of acquisition and progression of HPV infection. Compared to HIV-
seronegative men, infection with HIV is an additional risk factor for developing anal cancer, with 
relative risks (RR) for men seropositive for HIV of about 60 for in situ anal cancers, and about 
40 for invasive anal cancers (Frisch et al., 2000).       
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It also was reported that compared to men who have sex with men (MSM) seronegative 
for HIV, those who are seropositive have a 2-fold higher risk of anal cancer (Goedert et al., 
1998). Several studies examined the changes in the incidence of anal cancer and the introduction 
of highly-active antiretroviral therapies (HAART) (Bower et al., 2006; Hessol et al., 2007;                                                                                                                                               
D’Souza et al., 2008; and Piketty et al., 2008). The trends reported in the studies were consistent 
in that HAART therapy did not appear to have reduced the occurrence of anal cancer, as it did 
for other AIDS-related malignancies such as Kaposi’s sarcoma and non-Hodgkin lymphoma 
(Bower M et al, 2004; Diamond C et al, 2005). In the largest study (Chiao EY et al, 2005) 
involving general population-based cancer registries, anal cancer incidence increased from 0.6 to 
0.8 per 100,000 between 1973 and 2001. In the HAART era, there was a significant increase in 
incidence rates in both men and women, although more so in men. In 2006, Lampinen and 
colleagues reported that the increased risk of anal cancer among HIV-positive MSM can be as 
high as 140-fold when compared to HIV-positive men who are not practicing sex with men. The 
risk of HPV-associated anal cancer is 163-fold greater in young men with HIV than in young 
HIV-negative men (Breese P. et al, 1994). The progression of atypical squamous intraepithelial 
lesion (ASIL) to invasive anal cancer is influenced by a number of factors including: HIV 
seropositivity, infection with multiple HPV serotypes, and a high level of DNA of high-risk HPV 
genotypes (Uronis & Bendell, 2007). Cervical cancer is by far the most frequently recognized 
HPV-associated cancer, with an association with HPV 16 and HPV 18 (Clifford et al., 2003; 
Pretet et al., 2008). Many studies have shown that HIV-positivity is associated with an increased 
prevalence of cervical HPV infection and cervical intraepithelial neoplasia (CIN) (Palefsky J, 
2006).        
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Women with HIV or in a relationship with HIV-positive individuals are at increased risk 
for anal and cervical cancer as well as genital warts. In women who are HIV-HPV co-infected, 
lesions tend to be high-grade with a shortened interval between infection and invasive cancer 
(Apgar BS and Brotzman G, 1999). HIV-HPV co-infection is thought to increase the risk of anal 
carcinoma by 30 times (Sobhani et al, 2004), and these women have a 6.8-fold greater                                                                                                                    
risk of invasive anal cancer when compared with HIV-negative women (The National Cancer 
Institute Women’s Health Report, 2007). 
HPV 16 is found in an even higher proportion of anal cancers than cervical cancers (Fox P, 
2006). Likewise, anal cancer may be preceded by a series of precancerous lesions, known as anal 
intraepithelial neoplasia (AIN). The incidence of anal cancer is elevated in HIV-negative MSM 
and is even higher among HIV-positive MSM (Chin-Hong PV & Palefsky JM, 2005). A recent 
review conducted by the International Agency for Research on Cancer (IARC) concluded that 
while cervical cancer is virtually entirely related to HPV, other sexually-transmitted rare cancers 
are also associated with HPV to a varying extent: penile cancer at 40%, anal at 90%-95%, 
vulvar/vaginal at 40% and oropharyngeal at 12% (Munoz N. et al, 2006). The current estimated 
worldwide burden of cancer cases caused by HPV, and by HPV 16 and 18, is 5.2% and 3.7%, 
respectively (Parkin DM, 2006).                                                                                                                                                     
As a result of this evidence, a number of studies have recommended that all HIV-infected                                                                                                                                                  
individuals should be screened for HPV-related disease for early detection and treatment given 
the heightened risk of persistent HPV infection, malignant transformation, widespread disease 
and frequent recurrences (Palefsky JM, 2005). 
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1.3 Laboratory Definition of HPV infection 
Human Papillomavirus (HPV) is a virus that can lead to abnormal tissue growth (warts) and 
result in changes to the affected cells. Persistent infection with certain types of HPV can lead to 
cervical cancer, as well as anal, vaginal, vulvar, penile and oropharyngeal cancers (National 
Cancer Institute (NCI) Dictionary, http://nci.nih.gov/dictionary/). 
The HPV family is ubiquitous in the human population and more than 140 virus types have been 
identified (de Villiers et al., 1997). The viruses are small double-stranded DNA viruses with a 
genome of approximately 8kb that specifically target the basal cells of the epithelial mucosa (zur 
Hansen & de Villiers, 1994) and the metaplastic cells at the squamocolumnar junctions of the 
cervix (transitional zone - TZ) and anus (above dentate line). Additionally, HPV may infect the 
glandular epithelium of the endocervix, resulting in neoplasms, such as adenocarcinoma in situ 
or invasive adenocarcinoma. Visually-detectable HPV infections may manifest as warts. A 
history of anal warts (Condyloma Acuminata) increases the risk of anal squamous cell carcinoma 
10-fold (Bonnez W & Reichman RC), and approximately 50% of patients with anal squamous 
cell carcinoma also have a history of anal warts (Ryan DP et al, 2000). 
Low-risk HPV types (6, 11, 34, 40, 42, 44, 53, 54, 55, 57, 61, 70, 71, 72, 81, 84) are associated 
with benign lesions such as warts (Condyloma Acuminata), while infections with probable high-
risk (26, 53, 66, 68, 73, 82) and high-risk HPV types (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 
59) have the potential to progress into malignant lesions.  
There is also a large group of Unknown Effect HPV genotypes (30, 74, 85, 86, 87, 89, 90, 
CP6108 and IS39).   
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1.4 Natural History and Pathogenesis of HPV infection 
The overwhelming majority of patients with ano-genital cancer show serological, 
histopathological or molecular evidence of prior infection with HPV, and viral DNA sequences 
can be detected in their tumor tissue. Clinical pathological studies also provide strong causal 
evidence for HR HPV DNA in high-grade anal dysplasia and cancer (Abbasakoor F & Boulos 
PB, 2005; Gervaz P et al, 2006). In case-control studies using polymerase chain reaction (PCR), 
a highly sensitive assay for HPV DNA, between 80% and 100% of anal biopsy specimens 
contained HR HPV DNA, primarily HPV 16 (OHTA Series, 2007).                                              
There is also molecular evidence that high-risk HPV viruses integrate into anal cells (Zbar AP et 
al, 2002; Martin F & Bower M, 2001). High-risk viruses encode for at least three oncoproteins 
with growth-stimulating and transforming properties: E5, E6, and E7. The “E” designation 
indicates that these primary oncogenes are expressed early in the HPV life cycle. Integration of 
the HPV DNA results in a break in the E1 and E2 regions of the viral genome, leading to a loss 
of the E2 protein function and subsequent increased gene expression of E6 and E7, whose 
cooperation is needed to maintain the malignant cell expression in vitro. The products of these 
two genes alter the host cell metabolism to favor neoplastic development. Werness et al (1990) 
showed that the E6 proteins from HPV 16 and HPV 18 are capable of binding to p53 protein of 
the host cells. This binding promotes the degradation of p53 via the ubiquitin pathway (Scheffner 
et al., 1990 & 1993). Subsequent work has shown that the E6-mediated degradation of p53 is 
dependent upon a cellular protein, called E6-associated protein or E6-AP (Huibregtse et al., 1991 
& 1993). An effect of this targeted degradation is to prevent apoptosis of the infected host 
epithelial cells. The host cells telomerase is also activated, further augmenting oncogenic 
changes.  
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A natural consequence of the E6-induced degradation of p53 is the inhibition of both p53 growth 
and apoptotic functions of the normal cell cycle.  Once squamous and squamocolumnar                                                                                                                                                
tumor cells metastasize, mutations within p53 become more frequent (Crook & Vousden, 1992). 
This seems to indicate that the presence of mutant p53 gives cells a competitive advantage over 
cells in which p53 activity is not abrogated by E6 proteins. This supports the idea that mutants of 
p53 can have a dominant-negative phenotype. In order to have a productive infection, HPV types 
must infect keratinocytes in the basal layers of the epidermis. HPV undergoes vegetative 
replication only in differentiating epithelium, and the virus requires cellular DNA replication 
proteins in order to replicate its own DNA. Both of these proteins (E6 & E7) are expressed in 
anal neoplasia (Da Costa MM et al, 2002). The premalignant changes seen in cervical high-grade 
dysplasia (HSIL) and the greater degree of angiogenesis and apoptosis (natural cell death) than 
there is in the normal tissue are also seen in high-grade anal dysplasia (Little VR et al, 2000; 
Mullerat J et al, 2003).  
The major steps in the carcinogenesis pathway have been summarized by Moscicki AB 
and colleagues in 2006. Initially it requires an infection with one or more HR HPVs, and then 
viral persistence occurs rather than clearance, it follows by clonal progression of persistently 
infected epithelium to precancers, and finally, leads to invasion into the underlying tissue. The 
low- and high-risk HPVs differ in their sites of DNA replication within the differentiating 
epithelium (Doorbar et al., 1997). The low-risk HPV types generally replicate only in the lower 
levels of the stratified epithelium where the keratinocytes are still undergoing normal cell 
division. In contrast, the high-risk HPVs replicate their genomes in the higher levels of the                                                                                                                                                    
epithelium where the keratinocytes would have normally entered the process of terminal            
differentiation and switched off DNA replication. Thus, the high-risk HPV types stimulate cells 
to replicate DNA in a more unnatural environment than the low-risk HPVs.                                 7                         
 
 
1.5 Tumorigenic Potential of HPV 
Human Papillomavirus (HPV) infection is a significant source of morbidity and mortality 
worldwide. Management entails removal of discrete lesions and monitoring for recurrences. 
Prophylactic vaccines have become available and hold promise to significantly reduce the burden 
(morbidity and mortality) associated with HPV infections. A bivalent vaccine (Cervarix) has 
been formulated to protect against the two most common high-risk HPV types for cervical 
cancer, HPV 16 and 18.  The second, a quadrivalent vaccine (Gardasil) targeting HPV 16 and 18                                                                                                                                               
and the two most common low-risk types, HPV 6 and 11, is widely available in Canada. The 
vaccines contain papillomavirus-like particles (empty shells of viral structural proteins) that 
produce a neutralizing antibody response, which is believed to prevent papillomavirus from 
infecting host cells. The Society of Obstetricians and Gynecologists of Canada estimates that 
10% to 30% of the Canadian female adult population is infected with HPV. This is in line with 
research from the US and Europe which has shown that 10% to 40% of sexually active women 
are infected by HPV at any one time (http://www.hpvinfo.ca/health-care-professionals/what-is-
hpv/incidence-and-prevalence-of-hpv-in-canada/).                                       
Approximately 6.2 million new HPV infections occur in the United States every year. In 2004 
alone, approximately more than 20 million individuals were infected (Centers for Disease 
Control and Prevention, Genital HPV Infection: CDC Fact Sheet, CDCP 2004). 
Almost all cases of invasive cancers of the cervix, most other ano-genital tract cancers, and 
approximately 20%-25% of head and neck cancers contain oncogenic HPV viruses                                                                                                                                                           
(predominantly types 16, 18, 31, and 45 for cervical and other ano-genital tract cancers, and type 
16 for oropharyngeal cancers) (Zur Hausen, 1996; Munos et al., 2003).           
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In the “Study to Understand the Natural History of HIV/AIDS (SUN) in HIV-positive 
adults” by Vellozzi C and others (2009), the prevalence of HPV in the cervix and anus was 86% 
and 93% respectively, and for high-risk HPV types the prevalence rates were 68% and 85%, 
respectively. A history of anal sex was not predictive of an abnormal anal cytology. These 
results, although not completely independent of a history of anal intercourse, are explained by 
the anatomical proximity of the anus and the cervix. Squamous tumors of the anogenital region 
have similar histological, epidemiological, and pathogenetic properties (Melbye M & Sprogel P, 
1991; Dujovny N et al, 2004). The cervix, like the anus, has a transitional or transformational  
zone with an increased risk of dysplasia. In this area of transition, there is active changeover of 
columnar epithelium to squamous epithelium through the process of squamous metaplasia. 
Potentially-precancerous precursors of the epithelium, or dysplasia; are referred to as anal 
intraepithelial neoplasia or AIN when developing in the anus, and cervical intraepithelial 
neoplasia or CIN when developing in the cervix. Dysplastic cells have abnormal changes, 
however they do not show evidence of invasion into surrounding tissue. The most severe form is 
called carcinoma in situ, where the cells appear like cancer cells, but have not invaded beyond 
the basement membrane (membrane separating epithelium from tissue below).  
Intraepithelial neoplasia has been characterized into various grades, low (LSIL) and high (HSIL) 
based on their potential to progress toward invasive cancer. This process can be accelerated by 
trauma, healing and repair, such as might be expected to occur in receptive anal intercourse.  
Although several malignant forms can occur, squamous occurs most commonly (Rousseau Jr DL 
et al, 2005). 
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1.5.1 HPV-related HNSCC (Head & Neck Squamous Cell Carcinoma) 
The involvement of HPV in oral and oropharyngeal carcinogenesis was first proposed by 
Syrianen and colleagues in 1983. Several studies have reported HPV DNA in normal, pre- and 
malignant oral mucosa, although many of them were small hospital-based cross-sectional studies 
(Hodge et al., 1985; Hoshikawa et al., 1990; Blot et al., 1994). More recently, larger studies of 
HPV DNA prevalence in the head and neck mucosa have shown that HPV may be an additional 
independent risk factor for a subset of HNSCC (Schwartz et al., 1998; Smith et al., 1998, 2004; 
Herrero et al., 2003; Hansson et al., 2005). Other studies suggested that despite the majority of 
cases of oral and oropharyngeal cancer being attributed to tobacco and alcohol usage, there may 
be differences between the tumors that develop in smokers/drinkers and those that develop in 
non-smokers/non-drinkers (Koch et al., 1999; Wiseman et al., 2003).  
A meta-analysis of cases from 1982 to 1997, examining the risk of HPV detection in normal, 
pre- and cancerous oral tissue, showed that the probability of HPV being detected in mucosa 
increased along with the degree of dysplasia (Miller and Johnstone, 2001). In a total of 4680 
samples from 94 studies, these investigators reported that the pooled probability of detecting 
HPV in normal oral mucosa was 10% (95%CI 6.1-14.6), in benign leukoplakia was 22% 
(95%CI=15.7-29.9), in oral intraepithelial neoplasia 26.2% (95%CI 19.6-33.6%), in verrucous 
carcinoma 29.5% (95%CI 23.0-36.8), and in oral squamous cell carcinoma 46.5% (95%CI  37.6-
55.5). HPVs 16 and 18 were detected in 30% of oral squamous cell carcinomas (OSCC), while 
other high-risk HPV genotypes were detected in less than 1% of head and neck tumors.  
There was substantial heterogeneity in detection rates between studies which may be attributed 
to several factors, including: variations in prevalence between geographic locations of the  
 
                                                                                                                                                        10 
 
 
studies, between head and neck anatomical sites (Kreimer et al., 2005), and multiple HPV 
detection methods (polymerase chain-reaction [PCR], in situ hybridization [ISH], and others).              
Two large studies strengthened the correlation between HPV-associated ano-genital 
cancers and HNSCC. The study by Frisch and Biggar in 1999 was designed to determine 
whether there was a risk of tonsillar or other HNSCCs among patients with HPV-associated ano-
genital cancers. The risk of tonsillar cancer (RR=4.3, 95%CI 2.7-6.7) or other HNSCCs 
(RR=2.3, 95%CI 1.7-3.0) was significantly increased in these patients. Patients with cancers 
unrelated to HPV had a relative risk (RR) close to 1. The study by Hemminki et al. in 2000                                                                                                                                         
investigated the occurrence of second primary cancers in the upper aero-digestive tract among 
135,386 women (Sweden Family Cancer Database) who were initially diagnosed with cervical 
cancer in situ or cervical carcinoma. The occurrence of first primary cancers among their 
husbands was also assessed. The overall standard incidence ratios (SIR) for females with 
carcinoma in situ was 1.86 with the highest SIR attributed to the larynx; and for females with 
invasive cervical cancer, the overall SIR was 2.45 with the highest SIR attributed to the 
hypopharynx. Husbands of women with carcinoma in situ and with invasive cervical cancers had 
an overall SIRs of 1.43 and 1.37 respectively, with the highest SIR attributed to the tonsils. Men 
are slightly more prone to HPV-related oral tumors than women. A research published in the 
Journal of Clinical Oncology in February 2008 reported that the incidence of HPV-related oral 
squamous cell carcinomas in the United States increased significantly from 1973 to 2004, 
particularly among white men at younger ages. The increases might have been the result of 
changing in these young men’s sexual behavior (Harrington K, 2015). 
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The literature associating oral SCC and HIV infection is limited to a few case series, which show 
a younger age group (median age 40–45 years), more advanced local disease, and a higher tumor 
stage compared with non-HIV-positive oral SCC patients (Singh B et al, 1996; Roland JT Jr et 
al, 1993).    An epidemiological study conducted by UK researchers in Kenya (Butt FMA et al, 
2012) identified 200 HIV-positive patients with an orofacial malignancy, of whom16 (8.0%)                                                                                                                                  
had oral SCC. The female-to-male ratio was approximately 1:1, and the age range was 17 to 43 
years (mean age 31.7 years). The majority  (68.8%)  of  their  patients  denied  using tobacco  or  
alcohol,  while  the  remainder (31.2%) used one or both. The oral cavity sites affected were the 
tongue or the floor of the mouth (62.5%), the buccal mucosa (12.5%), the lower lip (12.5%) and 
the maxillary or mandibular alveolus (12.5%). The majority (62.5%) of HIV-positive patients  
had TNM stage III or IV disease (Tumor, Node, Metastasis system for cancer staging created by 
the American Joint Committee on Cancer [AJCC]), while the rest (37.5%) had stage I or II 
disease. Evidence supports the idea that HNSCC is a multifactorial disease with at least two 
pathways, one driven by smoking and alcohol consumption, with another driven by HPV.  
Although these pathways are possibly distinct, HPV infection and smoking are not mutually 
exclusive (Braakhuis et al., 2004; Ragin et al., 2004; Ferris et al., 2005). 
 
1.5.2 Anal Cancer in HIV-positive Adults 
Anal cancer is similar to cervical cancer biologically, including a causative association 
with human papillomavirus (Hoots, Palefsky et al., 2009). Within the anal canal the 
squamocolumnar junction (TZ) is anatomically very similar to the cervical squamocolumnar 
junction (TZ) on the cervix; these junctions are typically areas of squamous metaplasia, which 
are also present on the cervix.                                                                                                        
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These areas are especially susceptible to the oncogenic effects of HPV. It is in these areas that 
the basal cells are often closest to the surface which can facilitate infection by HPV.                                                                                                                                                
The equivalent of high-grade CIN, high-grade anal intraepithelial neoplasia (HGAIN), is known 
to progress to anal cancer (Watson et al., 2006). Several recent population-based studies showed 
that anal cancer rates have been increasing, and that the trend has been particularly dominant in 
urban populations, particularly those centres with high concentrations of homosexual males or 
men who have sex with men (MSM). Increasing rates have been reported in Copenhagen (Frisch 
M, et al 2003), London (Newsom-Davis T & Bower M, 2010) and San Francisco (Cress RD & 
Holly EA, 2003; Palefsky JM et al, 2005). The highest increase in anal cancer was reported in 
San Francisco, with rates in men aged 40 to 64 years increasing from 3.7 to 20.6 per 100,000 
from 1996 to 1999 (Chris RD & Holly EA, 2003). Human papillomavirus (HPV), a common 
sexually-transmitted disease that is almost universal in men infected with human 
immunodeficiency virus (HIV), is associated with the development of anal squamous cell 
carcinoma (Frisch M et al, 1993; Bower M et al, 2004; Cress RD & Holly EA, 2003 and 
Palefsky JM et al, 2005). The incidence of anal squamous cell carcinoma in HIV-positive men 
who have sex with men doubles that of HIV-negative MSM (Diamond C et al, 2005; Patel HS et 
al, 2007). HIV-positive MSM who practice receptive anal intercourse are twice as likely to 
develop anal squamous cell carcinoma as HIV-negative MSM. The incidence of HPV-associated 
anal cancer is high among HIV-positive MSM, and possibly in HIV-positive women (Kreuter A. 
et al., 2008, Shack L. et al, 2014). The risk of anal cancer compared  with the general population,  
is elevated  24-fold  in HIV-infected  women,  32-fold in  HIV-infected  men,  and  52-fold  in  
HIV-infected MSM (Chaturvedi AK et al, 2009 & Shiels MS et al, 2009).  
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For women, the occurrence of anal cancer is linked to their risk for other cancers in the 
anogenital region.  Cancer occurring anywhere in the anogenital region puts women at increasing     
risk for other primary or secondary cancers in the region, a phenomenon referred to as a field 
cancerization (Slaughter DP et al, 1953). Two larger cancer registry-based studies, one in the 
UK (Evans HS et al, 2003) involving 145,621 person-years of follow-up from 1960 to 1999, and 
one in Sweden (Hemminki K et al, 2000) that followed 135,386 women from 1958 to 1996, 
found significantly increased risks for other genital cancers after an initial diagnosis of cervical 
cancer. In the UK study, rates for secondary primary cancers after an initial diagnosis of cervical 
cancer were increased for the vagina (SIR=8.0, 95%CI 4.4-13.5), anus (SIR=6.3, 95%CI 3.7-
10.0), and vulva (SIR=1.9, 95%CI 1.0-3.3). In the Swedish study, increased rates for second 
cancers in the anogenital region after a primary cervical cancer were also reported, with the 
highest being for anal cancer (SIR=4.8, 95%CI 3.7-6.0).   
A broad-based cancer and acquired immune deficiency syndrome (AIDS) registry linkage 
study  examining the relationship of all HPV-related cancers in patients with AIDS reported 
significantly increased risks of HPV-related cancers in men and women (Frisch M et al, 2000). 
The RR for anal cancer was significantly higher for men than for women for invasive lesions 
(RR=37.9, 95%CI 33.0-43.4 vs. RR=6.8, 95%CI 2.7-14.0), in situ precursor lesions (RR=60.1, 
95%CI 49.2-72.7 vs. RR=7.8, 95%CI 0.2-43.6) and anal cancers. Although homosexuals with 
HIV exposure had the highest RR for anal cancer (RR=59.5, 95%CI 51.5-68.4), both male 
(RR=5.9, 95%CI 2.7-11.2) and female (RR=7.3, 95%CI 1.5-21.4) intravenous drug users also 
had an increased RR for anal cancer. 
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Highly active antiretroviral therapy (HAART) was introduced for widespread use in 1996, and 
since then the incidence of anal cancer has dramatically increased in the HIV-positive 
population, now exceeding the highest incidence of cervical cancer among women reported 
anywhere in the world  (Palefsky JM. et al, 2005).                                                                                                                                    
Three previously conducted studies reported a high incidence of anal cancer among HIV-positive 
MSM since 1996. One study was conducted by Piketty et al. and showed an incidence of anal 
cancer from a cancer registry in France of 75/100,000 person-years among HIV-positive MSM 
since 1999 (French Hospital Database). Patel and colleagues showed an incidence of 78/100,000 
person-years among HIV-positive MSM from a “Surveillance, Epidemiology, and End Results 
Program” - HIV registry match in the United States since 2000. D’Souza and colleagues showed 
an incidence of 137/100,000 person-years among HIV-positive MSM since 1996 among men 
participating in the Multicenter AIDS Cohort Study. The trends reported in the studies were 
consistent in that HAART therapy did not appear to have reduced the occurrence of anal cancer, 
as it did for other AIDS-related malignancies such as Kaposi’s sarcoma and non-Hodgkin 
lymphoma. In the largest study (Chiao EY et al, 2005) involving general population-based 
cancer registries, anal cancer incidence increased from 0.6 to 0.8 per 100,000 between 1973 and 
2001. Two studies, one in the United Kingdom (Bower M et al, 2004) and one in the United 
States (Diamond C et al, 2005) reported dramatically increased anal cancer rates in HIV 
populations after the introduction of HAART. In the UK study, the incidence increased from 35 
to 92 per 100,000 people with HIV. The overall incidence in the HIV cohort compared to the 
general population was 60/100,000 vs. 0.52/100,000. In the US study, rates in the general 
population among men aged 25 to 64 years increased from 0 to 224/100,000 from 1991 to 2000. 
The rate of anal cancer in the HIV cohort of men compared to men without HIV increased from 
98 to 352 per 100,000.                                                                                                                   15 
 
 
The prevalence of anal HPV infection in HIV-negative MSM of all age groups is high (19.8%), 
and does not decrease with age in HIV-negative men who remain sexually active with multiple 
sexual partners (Chin-Hong et al., 2004 The “EXPLORE” study).                                                
The data from a cohort of 1,409 HIV-negative MSM, aged 18 to 89 years and recruited from four 
US cities suggested that individuals might be susceptible to reinfection at least transiently,                                                                                                                                    
following re-exposure. This suggests that immunity to specific HPV types does not persist. It is 
considered that these men are repeatedly clearing and then becoming reinfected with HPV, 
giving rise to low- and high-grade anal intraepithelial neoplasia (AIN) which in many cases is 
transient. This fact would explain the absence of an age effect on the prevalence of AIN. The 
overall prevalence of HPV infection was 57% and was similar across all age groups.                                                                                                                                                    
The “EXPLORE” group also reported factors significantly associated with risk of HGAIN (high 
grade anal intraepithelial lesions): increasing number of male sexual partners (p=0.047), and anal 
infection with increasing HPV types (p<0.001). 
The absence of high-risk HPV at a single time point and from a single body site cannot 
guarantee that the virus is not present at another site or that the individual might not become 
infected at a later date (Fox et al., 2005). One problem here is the method of identifying the 
HPV. There is a probability that it may not always be picking up the infection; that perhaps 
individuals with HIV have a lower clinical threshold for infection than the general population. If 
this is true, the method of HPV detection becomes critical as the current assays include clinical 
thresholds which may not be fully applicable to the HIV-positive population. HIV-positive 
patients other than MSM can have AIN even where there has been no history of receptive anal 
intercourse; however the risk for these other groups appears to be much lower.  
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The study by Wilkin and colleagues in 2004 showed that 18% of men with no history of 
receptive anal intercourse had AIN based on cytology, compared with 65% for those who 
practiced receptive anal intercourse.  The difference still remains significant based on 
histological findings, at 23% compared to 52%.  
There is also an interpretive factor (or bias) that needs to be accounted for in both the 
histological and cytological interpretations. From 1980 to 2005, of the 20 533 estimated anal 
cancer cases, 1665 (8.1%) were HIV-infected. From 2001 to 2005, the proportion of anal cancer 
cases with HIV infection was the highest - 1.2% (95%CI 0.93%-1.4%) among females and 
28.4% (95%CI 26.6%-29.4%) among males (USA, Shiels MS et al., 2012). The increasing anal 
cancer incidence rates in the US were strongly influenced by the HIV epidemic in males but 
were independent of HIV infection in females.                                                                                                                                          
It is also well established that the risk of both prevalent and incident high-grade AIN 
increases as CD4 cell T count falls below 200 cells/mL (Kiviat et al., 1993; Palefsky et al., 
1998). Evidence suggests that unlike most other malignancies occurring in the HIV-positive 
population, anal cancer is potentially preventable, using methods similar to those used to prevent 
cervical cancer in women (Palefsky J.M., 2009). 
 
1.5.3 Cervical Cancer in HIV-positive Women 
In 1993, the definition of AIDS (acquired immunodeficiency syndrome) was revised to 
include women with invasive cervical cancer (ICC) (Maiman M et al, 1993 & Maiman M et al, 
1997). This decision was somewhat controversial as the incidence of cervical cancer had not yet 
increased among HIV-infected women. Nonetheless, the high prevalence of HPV coinfection 
and the increasing incidence of CIN lesions in HIV-infected women were of concern, strongly  
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suggesting that the risk of cervical cancer would rise over time. In fact, as shown in subsequent 
epidemiologic studies, a statistically-increased risk of ICC has been demonstrated among HIV-
infected women (Dorrucci M et al, 2003; Maiman M et al, 1994). Worldwide cancer of the 
cervix (CC) is the second most common cancer among women with an estimated 529,409 new 
cases and 274,883 deaths in 2008. About 86% of the cases, representing 13% of female cancers, 
occur in developing countries.                                                                 
Worldwide, mortality rates of CC are substantially lower than incidence with a ratio of 
mortality/incidence of 52% (IARC, GLOBOCAN 2008). In the last few decades, the incidence of 
cervical cancer has significantly declined with the introduction of cervical cancer screening to 
identify and treat women with cervical cancer precursor lesions (high-grade CIN or CIN II-III, 
and particularly CIN III). The treatment of high-grade CIN through a variety of modalities has                                                                                                                                                  
also substantially reduced the incidence of cervical cancer. HPV is one of the most common 
infections of the female genital tract, and it is also one of the most costly. HPV-associated health 
care costs include routine Pap tests, treatment of genital warts, follow-up of cytological 
abnormalities, and management of cervical malignancies. High-risk oncogenic HPV types 16 
and 18 are associated with 99.7% of all cervical cancers, as well as cytological abnormalities 
which carry significant health care costs and psychosocial morbidity. There is now considerable 
evidence that HPVs that are primarily transmitted through sexual contact are found in over 99% 
of the cases of invasive cervical cancer. Canadian researchers found that there was a long latency 
period between primary infection and cancer; the authors suggest that additional risk factors are 
involved in the process of tumor development (Mougin C and colleagues, 2001). These risk 
factors may include younger age, lower  education, nutritional status, multiple sexual partners, 
younger age at both first sexual experience and first pregnancy, and multiple pregnancies 
(p<0.003) (Bell MC. et al in 2011).                                                                                               18 
 
 
Also associated were recreational drug use, current smoking and history of sexually transmitted 
diseases. Although 10% to 40% of women in the general population can be infected by HPV 
during their sexual life, only a small minority of them is at risk for developing cancer.                                                                                                                          
The first population-based study to investigate the prevalence of HPV types in all grades 
of cervical neoplasia, as observed in a large sample of high-risk population, was conducted by 
Herrero R et al in 1999. As observed for HSILs, HPV 16 was the most common type (11.8%) 
followed by HPV 52 (5.6%) and HPV 51 (5.4% of positive subjects). Each tested precancerous 
lesion had at least one high-risk HPV type; however most were associated with multiple HPV 
types. In Canada, women account for 17.3% (11,191 cases) of the 67,442 positive HIV test 
results reported since November 1
st
, 1985, and represent a growing proportion of new HIV                                                                                                                                          
diagnoses (26.2% in 2008 compared with 11.7% before 1999) (www.phac-aspc.gc.ca/aids 
sida/publication/Survreport/2008/dec/index-eng.php).  
Women who are HIV-positive are at an increased risk for human papillomavirus infection, 
precancerous and cancerous lesions, as compared to HIV-negative women (Saslow D et al. 2002; 
Chin KM et al. 1998; Massad LS et al. 1999; Maiman M et al. 1998; IARC Working Group on 
the Evaluation of Carcinogenic Risks to Humans Human Papillomaviruses, 2007). Canadian 
researcher Pamela Leece in her 2010 retrospective cohort study “Cervical cancer screening 
among HIV-positive women” wrote: “33% (42 of 126) of the HIV-positive women who 
underwent cervical screening had at least 1 abnormal test.” Abnormal results were not 
significantly related to viral load; however, there was a significant relationship between lower 
recent CD4 T cell count (<200 cells/μL vs. ≥200 cells/μL) and having one or more abnormal Pap 
test results (OR=6.64, p=0.04). Rates of cervical screening in HIV-positive women in Ontario 
are estimated to be 68.6% during a 3-year period, indicating that HIV-positive women might 
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receive less screening than the general population (OCSP, Cancer Care Ontario, 
www.cancercare.on.ca/documents/OntarioBethesda2001.pdf - 2006).  HIV treatment guidelines 
recommend annual Papanicolaou (Pap) test for HIV-infected women. The US study conducted 
by Oster AM and colleagues in 2009 assessed screening prevalence and associated factors 
among HIV-infected women.  Of 2417 women, 556 (23.0%) did not report receiving a Pap test 
during the previous year. Not having a Pap test was associated with increasing age (adjusted 
odds ratio (AOR) = 1.3 per 10 years, 95%CI 1.1 to 1.4), and most recent CD4 count of less than 
200 cells/mL (AOR = 1.6, 95%CI 1.1 to 2.1) or unknown (AOR = 1.4, 95%CI 1.1 to 1.7; both 
vs. CD4 count of > or =200 cells/mL). Odds of a missed Pap test increased for women whose 
most recent pelvic exam was not performed at their usual source of HIV care (AOR = 2.6, 
95%CI 2.1 to 3.2). Nearly 1 in 4 women did not receive an annual Pap test.                                                                                                                        
The researchers concluded that HIV care providers should ensure that HIV-infected women 
receive annual Pap tests, recognizing that missed Pap tests are more likely among older women 
and women with low CD4 cell counts. Although there is a trend towards the association between 
older age and decreased likelihood to adhere to Pap smear screening in previous studies among 
HIV-positive women, in the current study, younger women were more likely to demonstrate non-
adherence to cervical cancer screening (Oster AM et al, 2009; Baranoski AS et al, 2011; Keiser 
O et al, 2006). Detecting cervical cancer in its earlier stages is life-saving. For instance, cervical 
cancer diagnosed at an early stage has a 92% 5-year survival rate (Saslow D et al, 2011). Given 
the increased cervical cancer risk among HIV-positive female smokers in particular, health care 
providers should give emphasis to the continuity of gynecologic care across women’s life cycles. 
Likewise, Oster and colleagues noted that attention should be given to ensure that women of all 
ages equally recognize the importance and benefits of Pap smear screening.  
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Researchers from the UK (Kuhn L et al, 2010) conducted a randomized clinical trial of 
two screen-and-treat strategies among 6555 women in Cape Town, South Africa, among whom 
956 were HIV-positive. Women were randomized to screen-and-treat utilizing either HPV DNA 
testing, a visual inspection (colposcopy) with acetic acid as the screening method, or placed in a 
control group. They were then followed for 36 months after randomization with colposcopy and 
biopsy to determine the study endpoint of CIN II or higher. In the control group, HIV-positive 
women had higher rates of CIN II or higher, detected by 36 months (14.9%), than HIV-negative 
women (4.6%, p = 0.0006). Screen-and-treat utilizing HPV DNA testing significantly reduced 
cervical intraepithelial neoplasia grade II or higher through 36 months in both HIV-positive    
(RR=0.20, 95%CI 0.06-0.69) and HIV-negative women (RR = 0.31, 95%CI 0.20-0.50). 
Reductions in the visual inspection with acetic acid-and-treat group were less marked.   
 The clinical presentation of cervical cancer in HIV-positive women tends to be more aggressive 
than in the general population, with many patients presenting with advanced-stage disease 
(Klevens RM et al, 1996). Diagnosis is often delayed due to misinterpretation, as many of the 
systemic signs of cancer, such as unexplained weight loss, low-grade temperatures and/or 
lymphadenopathy, may initially be attributed to the underlying HIV or another infection. In a 
study of 16 HIV-seropositive women with ICC, comparisons were made with 68 HIV 
seronegative women. The HIV-infected women were more likely to have high-grade tumors, 
lymph-node involvement and squamous cell pathology. While the stage of cervical cancer did 
not correlate with CD4 T levels, the CD4 status did influence treatment outcome. Patients with 
CD4 counts greater or equal to 500cells/mL demonstrated a more favorable response to 
treatment. Nonetheless, the median survival for the HIV-infected women was only 9 months and 
ultimately, more women died from cervical cancer than from AIDS (Schiffman M. et al, 2007).  
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During the pre-study and study periods, more than thousand of relevant articles have been 
reviewed and systematically updated in Introduction Chapter. More than 200 of them are listed 
in the Reference section of the thesis. Table 1 shows findings from some Canadian and 
international studies that investigated risk and incidence of HPV-associated precancerous lesions 
and cancers. 
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Table 1: Findings from Canadian and International Studies on Risk and Incidence of HPV-
associated Precancerous Lesions and Malignancy 
 
Author, Country, Journal & 
Year of publication 
Title of the Study Key Findings 
Shack L., Lau H.Y., Huang L. 
et al. Alberta, Canada 
CMAJ, 2014 
 
Trends in the incidence of human 
papillomavirus-related noncervical 
and cervical cancers in Alberta, 
Canada: a population-based study 
The annual percentage of the SIR increased for 
each 5-year interval of the study period: 
 
For oropharyngeal cancers (men – 3.4, p<0.001; 
women – 1.5, p=0.009) 
 
For anal cancers (men – 1.8, p=0.008; women – 
2.2, p<0.001) 
 
For cervical cancer (among women 75-84 years 
– 3.5, p=0.04) 
 
Shiels M.S., Pfeiffer R.M., 
Chaturvedi A.K, et al. USA 
J Natl Cancer Inst, 2012 
Impact of the HIV Epidemic on the 
Incidence Rates of Anal Cancer in 
the United States 
During 1980–2005, of the 20 533 estimated anal 
cancer cases, 1665 (8.1%) were HIV-infected.  
During 2001–2005, the proportion of anal cancer 
cases with HIV infection was the highest—1.2% 
(95% CI = 0.93 to 1.4%) among females & 
28.4% (95% CI = 26.6 to 29.4%) among males. 
 
Gaisa M., Sigel K., Hand J. et 
al. London, England 
AIDS, 2014 
High rates of anal dysplasia in 
HIV-infected men who have sex 
with men, women and heterosexual 
men 
Among 728 HIV+ people:  
Anal SCC (OR (95%CI)=2.2 (1.3-3.7) 
 
Anal HSIL in 32% of MSM, 26% of women, 
23% of heterosexual men  
 
Berry J.M., Jay N., Cranston 
R.D. et al. USA 
Intern. Journal of Cancer (IJC), 
2014 
Progression of anal high-grade 
squamous epithelial lesions to 
invasive anal cancer among HIV-
infected men who have sex with 
men 
During 1997-2011, 138 HIV-infected MSM were 
diagnosed with anal & perianal SCC.  
 
Anal cancer incidence is 80 times higher in 
HIV+ MSM than men in the general population. 
In 2012 this incidence was 131/100,000 in North 
America 
 
Moscicki A.B., Palefsky J.M. 
USA. Journal of Low Genital 
Tract Disease, 2011 
Human Papillomavirus in Men: An 
Update 
90% of anal cancer due to HPV 16 & 18 
 
70% of cervical cancer due to HPV 16 & 18 
 
Chaturvedi A.K., Madeleine 
M.M. et al. USA 
J Natl Cancer (JNCI), 2009  
Risk of Human Papillomavirus-
Associated Cancers among Persons 
with AIDS 
From 1996 to 2004: 
SIR (95% CI) of all HPV-associated cancer 
in situ=8.9 (8.0-9.9) 
SIR of anal cancer=34.6 (30.8-38.8) 
SIR of oropharyngeal cancers=1.6 (1.2-2.1) 
 
Silverberg M.J., Lau B., Justice 
A.C. et al. USA 
Clin Infect Dis, 2012 
Risk of Anal Cancer in HIV-
Infected and HIV-Uninfected 
Individuals in North America 
SIR (95%CI) of anal cancer=80.3 (42.7-
151.1) for HIV+ MSM and 
SIR (95%CI) of anal cancer=26.7 (11.5-
61.7) for HIV+ men compared with HIV-
uninfected men 
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1.6    Problem Statement and Hypothesis 
The risk of HPV associated malignancies is genotype-dependent. However, from the 
standpoint of HPV epidemiology, there is a lack of information on HPV genotype distribution 
and epidemiology of HPV-associated anal, oropharyngeal and cervical cancer among those 
living with HIV/AIDS (PHAs) in Atlantic Canada. This prospective cohort study, involving 
PHAs treated at the Infectious Diseases clinics in Atlantic Provinces aimed to reduce this 
information gap. While HPV prevalence is likely to be high in the target population, testing for 
the high risk (HR) HPV genotypes and associated cytological abnormalities should identify those 
at increased risk of malignancy. Moreover, determining the HPV genotype will be beneficial in 
assessing the relative risk and detecting the malignancy earlier, which will also be quite useful as 
a part of ongoing HIV disease management. 
The main research hypothesis in this study is that the incidence of HPV-associated anal, 
oropharyngeal and cervical cancers is higher among HIV-infected adults living in Atlantic region 
of Canada than their incidence in the Canadian general population. The aims of this study were 
(1) to reduce the information gap on HPV genotype distribution and epidemiology of HPV-
associated cancer among those living with HIV/AIDS in Atlantic Canada (2) to examine and 
quantify the relationship between precancerous lesions and cancers (anal, oropharyngeal and 
cervical) and HR HPV genotypes (3) to examine the relationship between precancerous lesions 
and cancers and predictors of HPV-related diseases. The following components were measured 
(i) self-reported history of unprotected sex (ii) self-reported history of sexually-transmitted 
infections (iii) self-reported number of sexual partners during the previous year (iv) self-reported 
history of smoking (v) annual prevalence of HPV genotypes over a four-year period (vi) annual 
levels of CD4 T cell count and plasma HIV RNA viral load over a four-year period.                                                                                                  
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1.7 Research Questions, Objectives and Purpose of the Study 
The author of this thesis studied exposure to HPV infection of HIV-infected individuals 
living in Atlantic Canada from 2009 to 2015. The study intended to answer the following 
questions: (1) What was the prevalence of HR oncogenic HPV genotypes in HIV-positive adult 
population in Atlantic Canada at baseline and three years of follow-up? (2) Were the HR 
oncogenic HPV genotypes associated with underlying anal, oropharyngeal and cervical 
premalignant lesions and malignancy? (3) Were the detected premalignant lesions and 
malignancy associated with patients’ demographics and behaviors as well as with patients’ health 
status? 
The objectives of the study were: 
To determine the prevalence of HR HPV genotypes in HIV-positive adults at baseline and 
throughout the years of observation 
To investigate association between these HPV genotypes and diagnosed precancerous lesions 
and cancers 
To investigate association between precancerous lesions and cancers and their potential 
predictors such as HIV markers (CD4 T cell count and HIV RNA plasma load), smoking, history 
of STIs, number of sexual partners, number of HPV types in a specimen, and history of 
unprotected sex.  
     Atlantic Canada is currently poised to effectively establish an HIV-HPV surveillance 
network. This capacity comes from the two Atlantic Canada initiatives: the Atlantic 
Interdisciplinary Research Network (AIRN) formed in 2005, and the Atlantic Canada HIV 
Education Network (ACHIVE) established in 2002. From the standpoint of the strength of the 
existing Atlantic Canada networks, it is a sound prospect to establish an “Atlantic Canada HIV-
HPV Surveillance Network” which could provide valuable information and serve as a model   25                                                                                                                                                        
 
 
to the rest of Canada. The study data and results might also be quite useful and included as a part 
of ongoing HIV patient care and management. They can potentially initiate some changes in the 
primary care policies with follow-up recommendations for the annual anal screening of all HIV-
infected adults, regardless of age and gender. The screening procedure would advisedly include 
both a visual inspection of the perianal region, and a digital rectal/anal examination (DRE/DAE) 
with anal specimen collection for the cytology evaluation and HPV genotyping. Furthermore, 
determining HPV genotype prevalence is beneficial in assessing the risk of acquired malignancy 
and will provide useful information in the era of genotype-specific HPV vaccination. Finally, 
findings from this study contribute to the national data on genotype distribution and add to the 
existing body of knowledge on HIV-HPV co-infection. 
 
1.8 Thesis Outline 
         Chapter 1 presents an introduction to the research, a rationale for the study, the research 
hypothesis and the specific research questions. Chapter 2 provides information about the study 
design, settings and population, and describes all techniques, tools, guidelines and classifications 
that were used for the research purpose. Chapter 3 presents the results from the analyses. Chapter 
4 provides a discussion of the study key findings, policy implications, the study limitations and 
potential areas for future research. Chapter 5 provides the conclusions that were drawn from the 
study findings. 
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1.9 Statement of My Role in the Project 
I hold M.D. from the Azerbaijan State Medical University and worked as a primary healthcare 
physician for more than 15 years. My participation in this study started in November 2008, the 
time when applications for ethical approval were being drafted and submitted to HREAs at all 
research sites. For almost two years, from January 2009 to December 2010, I was working with a 
multidisciplinary team as a part-time Research Assistant II (CIHR-PHAC fellowship supporting 
my Master’s program). In January 2011, I was appointed as a Research Coordinator of this 
project and carried out the study logistics until its end in April 2015. I recruited and sought 
consent from participants in the ID clinic at the NLSJ site, coordinated the communication 
among the sites, initiated research-related discussions both on-line and at the annual ACHIVE 
gatherings, provided literature review and critical appraisal of evidence, assembled and shipped 
out the study supplies, collected data from the sites and laboratories, sent the cytology results to 
the site investigators, followed-up the patients’ referrals to specialists, created and maintained 
datasets, analyzed and interpreted data, prepared and presented posters and oral abstracts at 
national and international conferences, and with my supervisor, eventually published an abstract 
with the preliminary findings in Annals of Epidemiology (2013). I also prepared and submitted 
annual reports to PHAC, as well as renewals and amendments to HREA. Currently, I am 
finalizing my PhD thesis and drafting an article with the final findings. 
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CHAPTER 2 
METHODOLOGY  
 
2.1  Study Design 
This prospective cohort study was carried out from June 2009 to April 2015.  
 
2.2 Study Settings  
The study centers in Atlantic Canada were located in St. John’s, NL, Saint John, NB, 
Moncton, NB and Halifax, NS.  Patients from Prince Edward Island (PEI) were mainly seen in 
Halifax. A study poster with the PI’s contact info was distributed at the local HIV clinics 
(Appendix A). Enrolment began in June 2009 and was ended in September 2012.  
All HIV-positive patients seen through the participating Infectious Disease (ID) clinics were 
approached by the clinic physicians or nurses to request participation in the study. They 
explained the study to the potential participants and obtained written consent. Consent was 
obtained using ethics board-approved consent forms with the clear understanding that the 
patients’ unique identification numbers (IDs) will be retained in order to conduct future patient 
follow-ups (Appendix B). Consent was also obtained to annually access the patient’s medical 
record information, such as current values (at the time of annual observation) of HIV RNA viral 
load, CD4 T cells count, treatment status, and history of sexually transmitted infections. This 
was done in order to correlate these factors with disease outcomes. All consenting participants 
were enrolled during a three-year period and were followed up, per usual care, for up to three 
years. During initial interviews, participants were administered a 26-item self-reported 
deidentified confidential Patient Questionnaire to obtain demographic and risk factor data 
(Appendix C).                                                                                                                               28      
 
 
The questionnaire was completed by the patient in a private room at the research site, and was 
then given to a research nurse in a sealed envelope. The sealed envelope was mailed to the PHL 
in St. John’s, NL along with the patient’s paperwork and specimens (Appendix H).   
                                                                                                                                                                        
At the time of enrolment, the clinic physician/nurse completed the 12-item Clinic Baseline 
Questionnaire with the current tests results related to the HIV markers and patient health status 
(Appendix D). The 9-item Annual Clinic Follow-up Questionnaire was completed for all study 
participants by their treating physician/nurse with the latest data for the year of observation 
during the three years of follow-up visits (Appendix E). They also completed the patient’s 
enrolment card in order to register the dates of the specimen collection at baseline and during the 
follow-ups (Appendix F).        
                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
2.3 Study Population                                                                                                                                          
Inclusion Criteria: 
All HIV-positive adults who attended ID clinics in the Atlantic Canada provinces from June 
2009 to September 2012. 
       Exclusion Criteria: 
HIV-positive people ≤ 18 years of age 
HIV-positive adults who are involved within other ongoing research projects 
HIV-positive adults with severe HIV-related and other health conditions   
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Sample Size Considerations and Calculation: All HIV-positive adults treated through the 
Infectious Diseases clinics participating in the research were approached by the clinic physicians 
or nurses to request their participation in the study. In 2008, Atlantic Canada had approximately 
800 routinely followed HIV-positive adults. Of them, 346 were enrolled in the study and of 
those, 263 were included in the final analysis. The flow chart below displays the changes in the 
sample size throughout the years of observation. 
Biostatistician was consulted and the recommendation was to retrospectively calculate 
the sample size in order to have enough power to detect clinically important differences between 
groups. The sample size (N) calculation was carried out by the SAS 9.4 Proc Power procedure. 
The incidence information, which was required in the calculation, was from the 2015 CDC “Fact 
Sheets” (http://www.cdc.gov/.../hpvcancer/). According to the CDC, in women 30 years of age 
and older the 10-year cumulative incidence of cervical cancer caused by the combination of 
HPVs 16 & 18 was 39% as compared to the 1.7% cumulative incidence of cervical cancer not 
caused by the HPVs 16 & 18.  
We observed our participants for 4 years which is almost half of the study time in the CDC 
report. Therefore, we assumed that our 4-year incidence of cancer caused by both HPV 16 and 
HPV 18 would be 20% as compared to 1% of the 4-year incidence of cancer being negative for 
HPVs 16 & 18. The calculated risk difference (RD) was (20% - 1%) = 19%. Based on our data, 
we observed the proportion of HPVs 16 & 18 being simultaneously positive in 44 (17%) 
patients. We needed to recruit 102 participants (N=102) in order to have Power=80%, β=0.20 
and α=0.05. In our study, 263 participants were included in the final multivariate regression 
analysis.     
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CHART 1: The Flow Chart of the Study Population throughout the Years of Observation 
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~800 HIV+ Adults in 
Atlantic Canada (2008) 
Excluded (400) 
400 (2009)  Young adults under 19 years of age 
 People involved within other 
ongoing research projects 
 People with severe HIV-related and 
other health conditions 
 People who refused the 
participation 
346 (2012) 
Enrolled from June 2009 to 
September 2012 
300 (2013) 
46 participants who had 
been enrolled later than 
majority and had incomplete 
data were discontinued from 
the study for the following 
reason: 
 
 The budget cutback for 
cytology and 
microbiology tests 
did not allow follow-
up of these 46 
participants 
261 (2015) 
Total 39 patients were lost in follow-ups: 
 
 8 patients withdrew from the study 
 16 participants moved from the 
study site and lost contact with the 
site team 
 6 patients became inactive because of 
their improved health from 
antiretroviral (HAART) treatment 
 9 patients died 
 
 
2.4 Study Milestones and Timeframe 
September 2008 – May 2009 
Acquiring the ethics clearance at all study sites 
 
June 2009 
Enrollment was started at all study sites with targeted 400 participants; the considered study due 
date was December 31, 2013 
                                                                                                                                                 
September 2012, ACHIVE in Halifax, NS 
Recruitment was finished with total 346 participants 
 
January-March 2013 
Negotiation with the Cytology & Microbiology laboratories; the expected study due date was 
extended to December 31, 2014 
 
September 2013, ACHIVE in Moncton, NB 
Number of the participants was reduced from 346 to 300 with the consequently reduced number 
of the specimens that still needed to be tested 
 
September 2014, ACHIVE in Saint John, NB 
The study due date was extended to April 30, 2015 
 
April 30, 2015 
The study was officially closed and the specimens’ collection was finalized 
 
May-September 2015 
Collection of the remaining materials from all of the project’s centers and both laboratories, data 
cleaning, statistical analyses, interpretation of the results 
 
September 2015, ACHIVE in Terra Nova, NL 
Presentation of the final report with the study findings to all study co-investigators 
 
October 2015 – December 2015 
Dissemination of the study results, drafting of the articles for the publication 
 
 
2.5 Specimen Collection and Centralization of the Data 
 The labels for each study site, the consent forms, enrolment cards and questionnaires were 
designed and printed prior to specimen collection. The study supplies were purchased and 
accumulated in the PHL storage space. Each province had its particular label color: New  
                                                                                                                                                                                                32 
 
 
Brunswick-red labels, Newfoundland-blue and Nova Scotia-green labels. Each label included the 
site name, patient’s personal identification number (PIN), and the type of specimen collected (A, 
O, C). For example, NLSJ 001 and checked A & O squares on the label indicated that this patient 
was a male (only anal and oropharyngeal specimens have to be obtained), his PIN in the research 
was 001 and he was from Newfoundland, St. John’s. In May 2009, the personal research kits 
were assembled and shipped out to each study center. The same procedure was repeated yearly 
during the three follow-up years. 
The personal kit for the screening year included (i) labeled paper-work (consent form, 26-item 
Patient’s Questionnaire, 12-item Clinic Baseline Questionnaire, and laboratory requisition form 
with the enrollment card) (ii) three Pap vials with a liquid media for the obtained specimens                                       
(iii) packs with Dacron and sterile cotton swabs (for anal and oropharyngeal specimens, 
respectively), including blue cervical brush for female participants (iv) paper bag and plastic 
biohazard bags for each collected specimen that was shipped back to the PHL in St. John’s, NL.  
The personal kit for the follow-up years included (i) 9-item Clinic Follow-up Questionnaire (ii) 
laboratory requisition (iii) two or three Pap vials (depending on the participant’s gender) (iv) 
packages with Dacron and cotton swabs, and/or cervical brush (v) paper and plastic biohazard 
bags. The shipment services were provided by FedEx Canada. In order to standardize collection 
among the study sites, the detailed guidelines for specimen collection (NYS DOH Guidelines 
recommendations on anal pap smears -Appendix G) were sent to the research sites at the 
beginning of the study. Trained personnel collected an oropharyngeal and anal swab specimens 
from all consenting males and females. Females were asked to provide an additional cervical 
specimen. This study used SurePath™ Liquid-Based Pap test (BD Diagnostics) supplies for 
specimen collection: SurePath™ vials with 10 ml of ethanol-based media, and blue cervical  
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brushes with the detachable end (http://www.bd.com/tripath/physicians/). The cervical 
transitional zone (TZ) is the site of origin of most cervical neoplastic lesions, and as in sampling 
for cervical cytology, was targeted in the study for exfoliated cells collection. Anal cytology 
samples were collected by rotating a water-moistened Dacron swab in the anal canal without 
direct visualization (blind or non-guided method) above the squamocolumnar transitional or 
dental zone (TZ), which is approximately 2 cm above the anal verge (NYS DOH AIDS 
Institute’s HIV quality-related, http://hivguidelines.org/Content.aspx). The oropharyngeal 
specimen was collected from the back side of the patient’s throat using a sterile cotton swab.  
The end sites of the collection devices were individually placed in a SurePath collection 
Pap vial. The sample-handling for all three specimens was similar. The resulting solution was 
stored at room temperature in the PHL and later used for the preparation of thin-layer slides for 
cytologic analysis. All specimens and completed paperwork from the study centers were sent to 
the Public Health Laboratory (PHL) in St. John’s, NL. The specimens were shipped under 
conditions that protected sample integrity (WHO Guidance on regulations for the transport of 
infectious substances) (http://www.who.int.csr/resources/biosafety/WHO HSE EPR 2008 
10/html). In the PHL, the vial’s content was divided in two parts and sent to different 
laboratories: one-third to the Eastern Health Regional Cytopathology Laboratory in St John’s, 
and two-thirds to the National Microbiology Laboratory (NML) in Winnipeg, MB for HPV DNA 
detection and HPV genotyping.    
The cytology reports were forwarded to the study physicians through the lead principal 
investigator and the study coordinator who analyzed and prepared milestone reports to the Public 
Health Agency of Canada (PHAC) in Ottawa. The detailed study Flow Chart is shown in 
Appendix J.                                                                                                                          
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2.6 Brief Description of the Existing Tests to Detect HPV Infection - WHO HPV                  
Laboratory Network (LabNet) Data (July 2010). 
 
There are two tests available to detect the presence of HPV viral DNA in a cell: the 
Hybrid Capture II test and the DNA PCR test (Chin-Hong PV & Palefsky JM, 2002). The Hybrid 
Capture II test is a more general test that can detect the presence or absence of the high-risk 
forms of the virus, but cannot specify their subtypes. Its advantages are that it is quick and less 
expensive compared to PCR tests. The PCR test can detect the type of HPV present, yet its 
sensitivity varies by the type of PCR system used. It is also generally more expensive and 
requires the presence of a greater viral load (A Global Review, 2008; BCCA Vancouver Centre; 
Canadas MP et al, 2004). 
WHO HPV Laboratory Network (WHO HPV LabNet) developed the manual on existing tests to 
detect HPV infection based on knowledge and experience gained through its International 
collaborative studies over the past several years. HPV cannot be cultured by conventional 
methods and is a cell-associated virus; therefore, HPV infection is monitored indirectly by 
detection of HPV DNA in a cellular sample obtained from a particular anatomic site. Lysis with 
or without extraction is required to release the viral DNA from the sample. Cellular DNA is also 
released at the same time and can serve as a control for the sample adequacy. Human 
papillomavirus (HPV) can be found in human epithelia in two forms, either individually or in a 
combination with episomal or extrachromosomal HPV particles. It can also be integrated into the 
human genome (Cooper K & Herrington CS et al, 1991). It was shown in previous studies that 
HPV DNA is present in three morphologically distinct forms in the nuclei of cervical 
precancerous and cancerous lesions by non-isotopic in situ hybridization (NISH) (Cooper K, et 
al, 1991). These forms were referred to as NISH signals types 1, 2, & 3, where a type 1 signal is 
diffused and present throughout the nucleus and represents episomal HPV virus.                       35 
 
 
A type 2 signal is punctuated and represents integrated HPV virus, and a type 3 signal is a 
combination of both forms. Therefore, a pattern regarding the physical state of the HPV DNA in 
cervical intraepithelial neoplasia (CIN) and squamous cell carcinoma (SCC) is that of episomal 
HPV virus predominating in the early stages of CIN and SCC, with integrated virus being 
detected more frequently in HPV-related high grade CIN and SCC. Furthermore, the latter may 
or may not contain episomal forms as well (Lehn H et al, 1988; DiLuca D et al, 1989). It should 
be kept in mind that detection of HPV DNA usually indicates current infection, but surface 
contamination cannot be excluded. Similarly, failure to detect HPV DNA does not exclude HPV 
infection as low-level infections or sampling errors, and infections at other anatomic sites need to 
be excluded.  
HPV infection is not treated, so current uses of HPV testing in screening and clinical 
diagnosis are directed towards detection of HPV-associated precancers that are treated, rather 
than to diagnose infection per se.  HPV cannot be easily propagated by standard in vitro culture 
systems, and in malignant tissue there are little or no infectious HPV particles. For these reasons, 
methods are based on the detection of HPV nucleic acids, in most assay formats, HPV DNA.  
Molecular methods for HPV detection can be grouped into two main categories (1) those that 
rely on signal amplification to detect the targets (2) those that rely on target amplification itself.                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
The WHO HPV LabNet has performed a series of proficiency testing studies since 2007. In total, 
81 datasets with HPV typing data were returned to World Health Organization for evaluation. 
These different assays are detailed in Table 2.  
In our study, we used the Roche Linear Array which was the most widely-used assay with results 
reported by 15 laboratories. The WHO HPV LabNet has agreed that a laboratory that performs 
HPV DNA detection and typing be considered proficient if it is able to detect 50 International  
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Units (IU)/5µL of HPV16 and HPV18 DNA and 500 genome equivalents (GE)/5µL of other 
HPV types. In addition, it should not give more than one false-positive result (FP) in the panel. It 
was recommended that genotyping assays should detect, at a minimum, the fourteen most 
common high-risk (HR) HPV types (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 & 68) and 
the two low-risk (LR) HPV types targeted by a current quadrivalent HPV vaccine Gardasil - 
HPVs 6 and 11 (Meijer CJ. et al, 2009).   
In view of the variety of HPV DNA detection and genotyping assays being used by laboratories 
worldwide, it is necessary to validate the assays both qualitatively and quantitatively in order to 
determine their following properties: (1) Sensitivity/Limit of Detection (2) Specificity (3) 
Accuracy (4) Reproducibility (5) Robustness (6) Linearity (7) Analytic Range based on ICH 
policies and procedures  
(International Committee on Harmonization, ICH Validation of analytical procedures: text and 
methodology, http://www.emea.europa.eu/pdfs/human/ich/038195en.pdf).                                                                                                                                                                                                                                                                  
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Table 2: The WHO HPV LabNet Dataset 
HPV Assay Type Number of 
Datasets 
HPV Region Targeted 
(Primers) 
All Assays 81 L1/E1/E6/E7 
1. Linear Array (Roche)* 15 L1 (PGMY) 
2. PGMY – RBH 7 L1 (PGMY) 
3. In-house Type-Specific PCR 7 L1/E6/E7 
4. In-house 16/18 Specific PCR 6 E6/E7 
5. InnoLiPA (Innogenetics) 6 L1 (SPF10) 
6. CLART (Genomica) 6 L1 (PGMY) 
7. DNA Chip (Biocore) 4 L1 
8. In-house Lineblot 4 L1 (GP) 
9. In-house PCR Luminex 4 L1 (GP or modified GP) 
10. In-house PCR Luminex 4 E6/E7 
11. In-house Microarray 3 L1/E7 
12. PCR – RFLP 3 L1 
13. Microarray (Genetel) 2 L1 
14. DEIA LiPA Assays 2 L1 (SPF10) 
15. In-house PCR E/A 2 L1 
16. Microarray (Papillocheck) 1 E1 
17. Type-specific PCR (GenoID) 1 L1 
18. In-house PCR Luminex* 1 L1 (PGMY – GP) 
19. PCR Luminex (Multimetrix) 1 L1 (GP) 
20. PCR E/A (GenoID) 1 L1 
21. In-house PCR Sequencing 1 L1 (PGMY – GP) 
 
*: HPV assays in italics (#1 & #18) were used in the study 
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2.7 HPV DNA and Genotyping Tests used in this Study 
The National Microbiology Laboratory in Winnipeg, MB conducted HPV DNA and 
Genotyping analysis for our study. Two HPV assay types were used (#1 and #18 in Table 1) for 
these purposes: The Linear Array Genotyping Test (#1) and The Luminex®-Based Genotyping 
Assay (#18 – In-house PCR Luminex L1 (PGMY-GP)). The laboratory supplies were provided 
by the Roche Molecular Diagnostics, which operates in the U.S. as the legal entity Roche 
Molecular Systems, Inc. (Roche Molecular Diagnostics Global website: 
http://molecular.roche.com/assays). Roche research assays and PCR technology have been 
widely used in landmark epidemiology studies around the world to characterize the incidence 
and distribution of HPV genotypes and for classification of the HPV types, as they relate to 
cervical cancer. 
The Linear Array HPV Genotyping Test (LA) is a qualitative in vitro test for the 
detection of human papillomavirus in clinical specimens. The test utilizes amplification of target 
DNA by the polymerase chain reaction (PCR) and nucleic acid hybridization, and detects 37 
HPV DNA types in cervical cells collected in PreservCyt solution (PreservCyt is a registered 
trademark of Cytyc Corporation, owned by Hologic). The Linear Array HPV Genotyping Test is 
registered for use in the European Union for detection of 37 high- and low-risk human 
papillomavirus genotypes, including those considered a significant risk factor for high grade 
squamous intraepithelial lesions’ (HGSIL or HSIL) progression to cervical cancer (numbers 
typed in bold). HPV genotypes include: 6, 11, 16, 18, 26, 31, 33, 35, 39, 40, 42, 45, 51, 52, 53, 
54, 55, 56, 58, 59, 61, 62, 64, 66, 67, 68, 69, 70, 71, 72, 73 (MM9), 81, 82 (MM4), 83 (MM7), 
84 (MM8), IS39, and CP6108.    
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In summary, the Linear Array assay has superior ability to detect HPV DNA with low and high 
β-globin references lines; is capable of detecting HPV genotypes in a multiple infection, which 
can occur in up to 35% of patient samples (Van Hamout D et al, 2009); has superior ability to 
detect HPV DNA and individual types that may be attributed to the use (Coutlee F et al, 2006) of 
(i) Standardized, quality-controlled reagents (ii) Primer concentrations that minimize competition 
due to coamplification. 
The Luminex®-Based Genotyping Assay was developed by a team of specialists from 
NML; PHAC, Winnipeg, MB; Cadham Provincial Laboratory; Manitoba Health and Healthy 
Living, Winnipeg, MB; PHL, St. John’s, NL; and Department of Medical Microbiology, 
University of Manitoba, Winnipeg, MB. This assay can simultaneously identify 45 mucosal HPV 
genotypes and was evaluated with the Roche Linear Array (LA) test. The study conducted prior 
to this project amplified single-stranded HPV DNA carrying a biotin tag that was generated 
using primers PGMY (Gravitt PE et al, 1998) and GP5+/GP6+ (Husman AM et al, 1995) in a 
nested PCR reaction. They used a set of 45 Luminex microspheres coupled with 45 unique HPV 
probes for detection and typing. A total of 149 cervical specimens collected in PreservCyt were 
utilized in the study. The Luminex method identified 45 vs. 37 mucosal HPV types either with or 
without cross hybridization, as compared to the Linear Array. It showed a higher sensitivity than 
LA test, 85 vs. 73 positive samples, and 171 vs. 164 total HPV types detected, with 47 multiple 
infections detected with both methods. On the other hand, the LA test showed slightly better 
sensitivity for detection of multiple infections with 3 or more types. Discordant samples included 
12 Luminex positive/LA negative results and 36 multiple infections in which the list of types 
was partially different between the two methods.                                                                                                                                                                                                                                    
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Four of these samples contained types not detected by the LA probes. No sample was completely 
discordant for HPV typing. The overall distribution of HPV types was similar between the two 
methods, with the exception of HPV 52, which was less frequently detected by the Luminex 
method compared to LA (8 vs. 18, respectively).  
In conclusion, the tested Luminex assay, when compared to the Linear Array (LA) test, offers 
more flexibility, lower cost and less hands-on time (Goleski VA et al, 2008). In our study, the 
NML administration kindly offered us the use of both PCR assays gratis (Linear Array and 
Luminex) during the screening year and only Luminex assay during the follow-up observations. 
 
2.8 Cytopathology and Histopathology Tests 
Screening for cervical or anal intraepithelial lesions involves the two-stage procedure: the 
first is Pap test for abnormal cytological findings, followed by a referral for an anoscopic 
examination (similar to a cervical colposcopic examination), and biopsy if necessary.  
In our study, The 2001 Bethesda System (TBS 2001) terminology was used to report the anal, 
oropharyngeal and cervical specimens’ cytology test results. Forty-four international 
organizations with interest in cervical cytopathology cosponsored the Bethesda System 2001 
Workshop along with the National Cancer Institute (NCI) in April 2001. The goal of the 
Bethesda System has always been to promote effective communication of relevant cytology 
findings between the laboratory and clinician to provide optimal patient care. The Bethesda 
System was developed primarily for cervical cytology specimens, and both the terminology and 
morphologic criteria reflect these. However, specimens from other body sites such as the throat, 
vulva, vagina, and anal/rectal samples may be reported using similar terminology (Solomon D & 
Nayar R, 2001).                                                                                                       
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The Bethesda System’s Second Edition provides a clearer indication of adequacy; specimens are 
now designated as “Satisfactory” or “Unsatisfactory” for evaluation: (1) For “Satisfactory” 
specimens, information on transformation zone (TZ) sampling and other adequacy qualifiers are 
included (2) For “Unsatisfactory” specimens, information on whether or not the laboratory has    
processed/evaluated the slide are included (whether the specimen was rejected or processed and 
examined, but deemed unsatisfactory for evaluation because of obscuring blood, etc.) 
 An adequate liquid-based preparation (LBP) should have an estimated minimum of at least 5000 
well-visualized/well-preserved squamous cells. For interpretation of adequacy for anal 
specimens, at least 8 nucleated squamous cells had to be visualized at high magnification (40X) 
to be considered adequate (Scholefield JH, et al, 1998; http://iris.ucl.ac.uk/research). This was 
derived using the ThinPrep criteria of 4 cells per HPF, and doubling it to accommodate the 
diameter of the sample being smaller for SurePath. If the specimen shows a cytologic 
abnormality, it is not necessary to report a specimen as unsatisfactory as the abnormality is 
reported independent of the cellularity when an abnormality is found. Studies of anal cytology 
have not found the presence of metaplastic or glandular mucosa necessary to reflect sampling of 
the transformation zone in contrast to cervical cytology where there needs to be at least two 
groups of 5 metaplastic or glandular cells. 
The 2001 Bethesda System maintains equivocal category atypical squamous cells (ASC) and 
simplifies its qualifiers to realistically reflect the inability of pathologists to accurately and 
reproducibly interpret these specimens (the reproducibility of ASC as an interpretation is around 
40%). All interpretations of ASC should be qualified as “Of Undetermined Significance”                                                                                                                                           
(ASC-US) or “Cannot Exclude HSIL” (ASC-H).  ASC-US is expected to comprise more than 
90% of ASC interpretations in most laboratories. ASC-H is a designation reserved for the  
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minority of ASC cases (expected to represent less than 10%) in which the cytological changes 
are suggestive of HSIL and require clinical investigation such as high resolution anoscopy 
(Solomon D et al, 2001). 
Squamous intraepithelial lesion (SIL) encompasses the spectrum of noninvasive cervical 
squamous epithelial abnormalities associated with HPV. In TBS, this spectrum is divided into 
low-grade (LGSIL or LSIL) and high-grade (HGSIL or HSIL) categories. Low-grade lesions 
encompass the cellular changes variously termed “HPV cytopathic effect” (koilocytosis) and 
mild dysplasia or cervical intraepithelial neoplasia 1 (CIN I). High-grade lesions encompass 
moderate dysplasia, severe dysplasia, and carcinoma in situ or CIN II and CIN III.  
Conceptually, HPV-associated abnormalities can be divided into transient infections that 
generally regress over the course of 1 to 2 years (mean is 18 months) and HPV persistence that is 
associated with an increased risk of developing a cancer precursor or invasive cancer (Bosch FX 
et al, 2002).   
These abnormality categories, along with the recommended management are demonstrated in 
Table 3. This Table was revised in January 2007 with support from the Nova Scotia 
Gynecological Cancer Screening Program, and Ontario’s Laboratory Proficiency Testing 
Program Guidelines. Consultation was held with leading pathologists and physicians in the 
Province of Newfoundland and Labrador, and was endorsed by the NL Medical Association 
(Cervical Screening Initiatives Program 2007, Clinical Management Guidelines). These 
guidelines were used for follow-up and management of all (anal, oropharyngeal and cervical) 
detected cytologic abnormalities.  As it was clearly demonstrated in the Table 3, epithelial cell 
abnormalities require further histopathology investigation such as colposcopy with biopsy for 
cervical histopathology, high resolution anoscopy (HRA) with biopsy for anal histopathology,                                                                                                                                                      
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and the biopsy of oral lesions. The correspondence of the findings from cytopathology laboratory 
with those from histopathology laboratory is necessary for the confirmation of the type of lesion 
or stage of malignancy to develop the strategy of their further treatment. The study main 
outcomes were precancerous lesions and cancers. Their management and necessity of further 
investigation (biopsy) was determined by specialist based on a severity of lesion. 
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                    Table 3: Clinical Management Guidelines (The 2001 Bethesda System) 
RESULT RECOMMENDED MANAGEMENT 
Specimen Adequacy Statement  
Satisfactory Routine Screening at annual intervals (unless the specimen adequacy statement is 
accompanied by a qualifier and subsequent recommendation). 
Unsatisfactory Repeat smear after 12 weeks. 
Negative  
NIL Negative for Intraepithelial Lesion Routine screening* If specific pathogen is present, treat as clinically appropriate. 
*In the presence of a gross abnormality with a negative Pap test, patient should be referred for Colposcopy 
Epithelial Cell Abnormalities  
ASC-US Atypical Squamous Cells of 
Undetermined Significance 
Women < 30 years of age: A repeat Pap test in six months is recommended; 
If abnormal, refer for Colposcopy. If negative, repeat in six months. After two negative Pap 
tests, return to routine screening 
Women > 30 years of age: HPV Positive*  Colposcopy and Biopsy 
Women > 30 years of age: HPV Negative*  Routine annual screening 
*HPV Testing will be done through the laboratory automatically for ASCUS results in women over 30 
years. A combined report will be issued. 
ASC-H Atypical Squamous Cells cannot 
exclude HSIL 
Colposcopy and Biopsy. 
LSIL Low Grade Squamous Intraepithelial 
Lesion 
Colposcopy and Biopsy. 
HSIL High Grade Squamous Intraepithelial 
Lesion 
Colposcopy and Biopsy. 
AGC 
Atypical Glandular Cells 
AEC – Atypical Endocervical Cells – Colposcopy and Endocervical Curretage (ECC) 
For women over 35, endometrial sampling is also recommended. 
AEMC – Atypical Endometrial Cells – Colposcopy and Endometrial Sampling (EM) 
NOS – Not Otherwise Specified – Colposcopy, ECC and EM Sampling 
FN – Favor Neoplastic – Colposcopy, ECC and EM Sampling. 
AIS Adenocarcinoma In Situ 
Squamous Cell Carcinoma 
Adenocarcinoma 
Colposcopy, Biopsy and endocervical curretage as recommended. 
Colposcopy and Biopsy. 
Colposcopy and Biopsy. 
Other  
Endometrial Cells in a woman over 40 (or a 
younger woman with unexplained vaginal 
bleeding) 
These findings should be interpreted in light of the clinical scenario. Clinical correlation is 
advised. Endometrial biopsy is recommended if post-menopausal or patient has abnormal 
pre-menopausal bleeding. 
 
In our study we used The Bethesda 2001 System and CIN Classifications to coordinate 
cytological and histological findings (Table 4).     
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Table 4: Correspondence of Cytological and Histological Findings 
(TBS 2001 & CIN Classifications were used in this study) 
 
 
Table 5 below provides description of the management procedures for the study participants who 
were diagnosed with the cell abnormalities in their specimens. If the Pap test abnormalities were 
persistent in the follow-ups, these patients would have had annual anoscopy or colposcopy with 
biopsy. 
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Table 5: Management Procedures of the HIV-infected Study Participants with Pap test 
Abnormalities 
Type of Specimen Site-specific Collection of Pap 
smear 
Management of Pap test abnormalities 
Anal Non-visualized specimen collection 
from anal canal using Dacron 
swabs 
 ASC-US & HPV+ 
Referral to GI surgeon for HRA & 
possible biopsy of lesion 
 
 ASC-H, LSIL & HSIL 
High Resolution Anoscopy (HRA) with 
biopsy, follow-up (treatment or repeat 
anal Pap smear in 3 months) 
 
 SCC in situ, Invasive cancer 
Treatment 
 
Oropharyngeal 
 
Specimen collection from back site 
of the throat using sterile cotton 
swab 
 ASC-US & HPV+ 
Referral to ENT specialist for oral 
examination & possible biopsy of lesion 
 
 ASC-H, LSIL & HSIL 
Biopsy of lesion, follow-up (treatment 
or repeat oral Pap smear in 3 months) 
 
 SCC in situ, Invasive cancer 
Treatment 
Cervical Cervical swab using cervical blue 
brush 
 ASC-US & HPV+ 
Referral to Gynecologist for colposcopy 
& possible biopsy of lesion 
 
 ASC-H, LSIL, HSIL 
Colposcopy with biopsy,  follow-up 
(treatment or repeat cervical/vaginal 
Pap smear in 3 months) 
 
 SCC in situ, Invasive cancer 
Treatment 
 
 Anal cancers were defined using International Classification of Diseases for Oncology, 3rd 
edition (ICD-O-3), topography codes C210 (anus, not otherwise specified) and C211 (anal 
canal).  
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Anal cancers were classified by histology as squamous cell carcinomas (ICD-O-3 codes 8050–
8089), adenocarcinomas (ICD-O-3 codes 8140–8309), carcinomas not otherwise specified (ICD-
O-3 code 8010), and other histological subtypes.                                                                                                                                                      
 
2.9 Statistical Analyses 
2.9.1 Data collection 
Data was collected from the following documents: (1) The self-reported 26-item Patient’s 
Questionnaire (PQ) (Appendix C) administered to all participants at enrollment (2) The 12-item 
Clinic Baseline Questionnaire (Appendix D) which was completed by the study co-investigators 
(physicians and/or nurses) at the enrollment (3) The 9-item Clinic Follow-up Questionnaires 
(CQ) from the three consecutive years of follow-up (4) The annually conducted laboratory tests’ 
results (Cytology, HPV DNA & Genotyping) (5) The annual measurements of the HIV markers 
(CD4 T cell count and HIV RNA load) (6) Histopathology reports 
SAS version 9.4 was used for the statistical analyses. All tests were two-sided with the 
significance at α < 5%.  
2.9.2 Dependent Variables 
In this longitudinal project, the exposure of the HIV-positive population to HPV 
infection was investigated. The dependent variables (Ys) in this study were incident HPV-related 
cancers (anal, oropharyngeal and cervical) and prevalent precancerous lesions. Those dependent 
variables were the study primary outcomes. 
2.9.3 Independent Variables                                                                                                      
The following independent variables (Xs) were extracted from the patient and clinical 
questionnaires and laboratory tests results used in this project:  
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Patient’s self-reported age, sex, education level, number of sexual partners, history of 
unprotected sex, history of sexually transmitted infections, smoking status; and annual 
measurements of CD4T cell counts and plasma HIV RNA viral load. They also included the 
detected HPV genotypes. Variables described as Predictors of the persistent HPV infection and 
its progression to neoplasia in the model included smoking status, HIV laboratory markers, and 
patient’s sexual behavior. Variables described as Cofactors in the model included age, sex, 
number of sexual partners, history of STIs and others.     
2.9.4 Descriptive Statistics 
Descriptive statistics were conducted to describe the characteristics of the sample studied 
stratified by age, sex, and the study sites. As there were four study sites (St. John’s, Halifax, 
Moncton and Saint John), the difference between groups was examined by using Chi-Square test 
for categorical variables and t-test for continuous variables to determine the level of significance.   
A preliminary analysis of patients’ age through Histogram 1 illustrated data that was normally 
distributed. Therefore, Mean (SD) and Frequency (Proportions) were provided for continuous 
and categorical variables respectively. The outliers (data points that are greater or less than 3 
standard deviations from the mean) can influence the average. The median as descriptive 
measure of CD4 T cell counts and HIV RNA load levels is more accurate than the mean to 
describe the central tendency of the data and to compare the variability of the data. 
Incidence Rate (Unadjusted) based on person-time (person years [PYs])) and Age Standardized 
Incidence Ratio (ASIR) using the Canadian general male population as a reference group were 
calculated. Their tabulated calculations with formulas are presented on pages  
2.9.5 Logistic Regression Models  
Logistic Regression (Univariate and Multivariate) was used to determine whether the patient’s 
self-reported variables were predictors of the HPV-associated cancers and precancers.              49                                                                                                                                                                       
 
 
The dependent variables were dichotomous or having only two outcomes (presence of 
lesion/cancer 1= yes, 0= no). The advantage of using logistic regression is that the estimates of 
the coefficients in the equations (βn) can be interpreted easily as they are presented as odds ratios 
(ORs). Logistic regression is part of generalized linear models or GLM and allows one to predict 
a discrete outcome from a set of independent variables that may be continuous, discrete or 
dichotomous. In this study, the regression models used the Maximum Likelihood Estimation 
method (MLE), as the distribution of the response variables was binomial (Munroe B., 2003). 
Steps in the building a Main Effects Model was built using the purposeful selection of 
variables. Univariate Logistic Regression (Y = β0 + β1X1) was carried out for each of the 
independent variables. All independent variables which were significant at 0.20 (p≤ 0.020) and 
non-significant but clinically important independent variables were included in the multivariate 
logistic regression model. Multivariate Logistic Regression model (Y = β0 + β1X1 +…+ βnXn 
+ ε) allows us to estimate the association between given independent variable and the outcome 
holding all other variables constant (i.e., when the remaining independent variables are held at 
the same value or are fixed). MLR model included all the significant (p< 0.20) and clinically 
important variables. Then, variables which were not significant at 0.05 were removed from the 
model. We run the Likelihood Ratio test to examine the significance of the variables that were 
removed in the above step. Then we assessed the confounding effects by dropping one variable 
at a time to estimate the changes in Beta (β) coefficients (≥ 15%). Finally, we checked linear 
assumptions of continuous variables. If they did not meet the linearity assumptions, they were 
replaced with categorical variables. Steps in building the Interaction Effects:  Interaction terms 
which should be clinically plausible were identified. A multivariate model included main effects 
and one interaction term on at a time; non-significant terms were removed from the model. Our 
Final Model includes main effects and all significant interaction terms.                                      50                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
 
 
CHAPTER 3 
 
STUDY RESULTS 
3.1 Descriptive Statistics 
 
The population mean age (SD) was 46.9 (9.3) years. The distribution of the study population 
by age is shown in Histogram 1. Of 300 patients at the baseline, 91.7% were males. At the end of 
the study, of 263 participants 93.2% were males.        
Histogram 1 
Distribution of the Study Population by Age (in years) 
 
 
                                                                                                                                                         
The population distribution by age categories and gender among the provinces is shown in Table 
6. The differences among the provinces were compared using Chi-Square test (Fisher’s Exact p 
value when the expected count of cell was less than 5): 
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Table 6: Distribution of the Study Population by the Site, Age Categories and Gender 
at the Baseline (N=300) 
 
Variable NLSJ 
N (%) =44 (14.7%) 
NBM 
N (%) =90 (30.0%) 
NSH 
N (%) =150 (50.0%) 
NBSJ 
N (%) =16 (5.3%) 
Age Categories N (%)* 
25 – 39 
40 – 59 
60 & > 
 
 
8 (18.2%) 
       33 (75.0%) 
         3 (6.8%) 
 
21 (23.3%) 
63 (70.0%) 
6 (6.7%) 
 
25 (16.7%) 
105 (70.0%) 
20 (13.3%) 
 
7 (43.8%) 
9 (56.3%) 
         0 (0.0%) 
Gender N (%) ** 
Male 
Female 
 
34 (77.3%) 
 
10 (22.7%) 
 
85 (94.4%) 
 
5 (5.6%) 
 
       142 (94.7%) 
 
 8 (5.3%) 
 
       14 (87.5%) 
 
2 (12.5%) 
 
    *: P=0.0814 from Chi Square test (not significant) 
  **: P= 0.0018 from Chi Square test (significant difference) 
 
 
Our findings from Table 6 showed that the distribution of the study population by age categories did not 
differ significantly across the study sites. The distribution by gender showed significant difference among 
the study sites with the highest female proportion at the NLSJ site (22.7%). 
 
A total of 39 (13%) participants were lost during the follow-up years with 87% of 
attrition rate: (1) Eight (20.5%) patients withdrew from the study (2) Sixteen (41%) participants 
moved from the study site and lost contact with the site team (3) Six (15.4%) patients became 
“inactive” because of their improved health from HAART (Highly Active Anti-Retroviral 
Therapy). The research visits were adjusted to the patients’ regular clinical schedule; therefore, 
these six patients did not have their follow-up visits for research purpose (4) Nine or 23.1% 
patients died. The change in the total number of participants by the study sites during the follow-
up observations is shown in Table 7:                                                                                                                                                                                                                                
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Table 7: Comparison of the Loss by the Study Sites throughout Follow-up Years 
Study Site Baseline 
 N 
1
st
 year F-up 
N 
2
nd
 year F-up 
N 
3
rd
 year F-up 
N 
Total Loss 
N (%) 
NLSJ 44 43 42 42                 2  
4.5% at NLSJ 
5.1% within total loss 
NBM 90 88 86 83          7 
  7.8% at NBM 
17.9% within total loss 
NSH 150 138 127 121               29* 
19.3% at NSH 
74.4% within total loss 
NBSJ 16 16 16 15                   1  
6.3% at NBSJ 
2.6% within total loss 
Total 300 285 271 261               39  
100% within total loss 
13.0% within cohort 
 
*: Chi Square test, p value<0.05   
                                                                                                                                                             
Our findings showed a significant difference in the loss to follow-up rates among the four study 
sites. The highest rate was observed at the NSH site (19.3%) and the lowest was observed at the 
NLSJ (4.5%). This might be explained by the facts that Halifax was the largest site and that this 
site experienced relocation of the research staff during the study years. Also, HIV-infected 
participants from Prince Edward Island were mainly treated in the Halifax ID clinics and had a 
tendency to move from one clinic to another. From 16 participants who moved from the study 
site and lost contact with the site team, twelve (75%) came from the NSH site. 
 
Participants lost to follow-up and participants retained in the cohort were compared in Table 8. 
Baseline characteristics were stratified by these two groups. 
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Table 8: Comparison of Baseline Characteristics between Participants Lost to Follow-up 
and Participants Retained in the Cohort 
 
Characteristic Lost to Follow-up (39) 
N (%) 
Remained in the Cohort 
(261), N (%) 
P value* 
 
Age, mean (SD) 
 
45.7 (10.6) 
 
47.2 (9.1) 
 
0.374 
Gender (males) 32 (82.1%) 243 (93.1%) 0.029 
       Smoking (yes) 19 (48.7%) 111 (42.5%) 0.492 
       Male Partners  
                                     0 
                             1 or 2 
                                   ≥3 
 
15 (38.5%) 
14 (35.9%) 
10 (25.6%) 
 
103 (39.5%) 
106 (40.6%) 
 52 (19.9%) 
 
 
0.479 
 
Unprotected Oral Sex 
(yes) 
 
17 (43.6%) 
 
128 (49.0%) 
 
0.607 
 
Unprotected Anal Sex 
(yes) 
 
8 (20.5%) 
 
47 (18.0%) 
 
0.663 
 
Ever on anti-HIV 
therapy 
 
31 (79.5%) 
 
240 (92.0%) 
 
0.036 
 
Currently on ARV 
therapy 
 
30 (76.9%) 
 
230 (88.1%) 
 
0.074 
 
CD4 cells count 
(<200 cells/mL) 
 
9 (23.1%) 
 
75 (28.7%) 
 
0.701 
 
History of Anogenital 
Warts (yes) 
 
13 (33.3%) 
 
95 (36.4%) 
 
0.615 
 
*: t test for continuous variable (age) and chi square test for all categorical variables 
 
There was a significant difference between two groups by their gender distribution with the 
higher proportion of males among the retained participants (p=0.029). The proportion of patients 
who have been on antiretroviral therapy prior to the study was higher among the retained 
participants as well (p=0.036). 
The causes of nine deaths were analysed, leading to two patients who reached the study 
endpoint (cancer) but died during the follow-up period being included into the final analysis.  
This brought the total to 263 participants. The two cases that were included despite the patients’ 
deaths were:                                                                                                                                   54 
 
 
Male patient who died of Tongue Cancer in 2010 with HPV 16 in his oropharyngeal specimen, 
and combination of HPVs 16 & 52 in his anal specimen, and male patient who died of Kidney 
Failure in 2011 but was previously diagnosed with Anal Invasive Squamous Cell Carcinoma 
with the combination of HPVs 11, 16, 39, 52 & 74 in his anal specimen. 
 
3.1.1. Descriptive Statistics for 300 Participants at the Baseline 
Data from the 26-item Patient’s Questionnaire was analyzed: 
Of 300 patients at the baseline, 271 (90.3%) had reportedly been on anti-HIV treatment 
sometimes previous to the study, and 260 (86.7%) were on antiretroviral therapy at the enrolment 
time. Of 263 patients at the end of the study, 232 (88.2%) have been receiving a combined 
antiretroviral therapy (ARVT). The majority (221(73.7%)) of participants did not have an AIDS-
defining illness previous to the study; 292 (97.3%) of them did not have any AIDS-defining 
events at the enrolment time, and almost all of them (261(99.2%)) were AIDS-free at the end of 
the follow-ups.    
The majority of the study participants (245 (81.7%)) had anal sex with condoms. The 
number of patients who had oral sex with condoms (or did not practice oral sex), and who did 
not use condoms during oral sex was almost equal (146 (48.7%) & 154 (51.3%), p=0.437).      
All 25 female participants had been screened for cervical cancer prior to the study within 
different time intervals from their last Pap test. Of those 25 females, 7 (28%) were in the “less 
than 6 months ago”; 4 (16%) were in “6 months to less than 12 months” and 6 (24%) females in 
“from 1 year to less than 3 years ago” categories. Four (16%) females had had it “from 3 years to 
less than 5 years”; one (4%) woman was last screened “5 and more years ago;” and three (12%) 
of them did not recall the date of the last Pap test.                                                                      
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The most important demographics and other patients’ characteristics are presented in Tables 9 
and 10 below: 
Table 9: Patients Demographics and Other Important Characteristics at Baseline (N=300) 
 
Variable  N (%)  
 
HAART (yes) 
 
271 (90.3%) 
AIDS-defining Illness (yes)   79 (26.3%) 
HPV vaccination (yes)  0 (0.0%) 
Undergraduate and Graduate Education (yes) 147 (49.0%) 
Smokers (yes) 132 (44.0%) 
History of Anal Pap Test (yes)   33 (11.0%) 
Number of Male Sexual Partners IQR=1 male partner/year 
History of Unprotected Anal Sex (yes)   55 (18.3%) 
History of Unprotected Oral Sex (yes) 154 (51.3%) 
History of STIs (yes) 193 (64.3%) 
History of Hepatitis C (yes)   31 (10.3%) 
History of Anogenital Warts (yes) 106 (35.3%) 
History of Genital Herpes (HHV-2) (yes)   46 (15.3%) 
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 Table 10: Patients’ Baseline Demographics and Behavior Characteristics by Gender, and 
the most frequently observed HPV genotypes stratified by Body Site and Gender (N=300) 
 
Characteristic Males (N=275) Females (N=25)           P value* 
Age, mean (SD) 46.7 (9.1)  41.6 (7.3) 0.006 
Unprotected Vaginal Sex (N/%)     8 (2.9%)   8 (32.0%) <0.0001 
Unprotected Oral Sex (N/%) 139 (50.5%)   6 (24.0%) 0.012 
Unprotected Anal Sex (N/%)   53 (19.3%)   2 (8.0%) 0.277 
Male Partners 
                                      0 
                              1 or 2 
                                    ≥3 
 
111 (40.4%) 
104 (37.8%) 
  60 (21.8%) 
 
  7 (28.0%) 
16 (64.0%) 
  2 (8.0%) 
 
0.031 
Anal HPVs 
                                    16 
                                    18 
                                    45 
                                    52 
 
  91 (33.1%) 
  41 (14.9%) 
  48 (17.5%) 
  49 (17.8%) 
 
  2 (8.0%) 
  1 (4.0%) 
  2 (8.0%) 
  2 (8.0%) 
 
0.01 
0.13 
0.22 
0.21 
Oral HPVs 
                                    16 
                                    35 
                                    45 
                                    72 
 
    5 (1.8%) 
    2 (0.7%) 
    2 (0.7%) 
    3 (1.1%) 
 
 
  0 (0.0%)  
 
N/A 
Cervical HPVs  
                                    16 
                                    18 
 
       N/A 
 
  4 (16.0%) 
  1 (4.0%) 
 
N/A 
 
*: t test for continuous variable (age) and chi square test for all categorical variables 
    
The findings from Table 10 showed that at the enrolment time the cohort males were 
significantly older than females (p=0.006). Higher proportion of females reportedly practised 
unprotected vaginal sex (p<0.0001); while a higher proportion of males reported history of 
unprotected oral sex (p=0.012).   The proportion of women who had 1 or 2 male sexual partners 
per year was higher than the proportion of men who reported the same number of male sexual 
partners per year (64.0% vs. 37.8%). The proportion of men with anal HPV 16 infection was 
significantly higher than proportion of women infected by the same HPV genotype and at the 
same body site (p=0.01).                                                                                                                          
                                                                                                                                                        57 
 
 
3.1.2. Descriptive Statistics for the Study Sites  
The tables below from 11 to 14 compare our findings among the study sites. This was a 
collaborative multicenter cohort study and the study co-investigators wanted to know the site-
related statistics as well. The comparison between the study sites was carried out by Chi Square 
test.                                                                                              
Table 11: Patients’ Demographics by the Study Sites at the Baseline (N=300) 
PARAMETER NLSJ 
(St. John’s) 
NBM 
(Moncton) 
NSH 
(Halifax) 
NBSJ 
(Saint 
John) 
P value* 
Patients, N (%) 44 (14.7%) 90 (30.0%) 150 (50.0%) 
 
16 (5.3%)  
Age, mean (SD)  
(min, max) 
45.2 (7.4) 
28-62 
 
45.9 (9.7) 
26-80 
48.7 (9.4) 
27-72 
41.8 (9.0) 
26-57 
0.0044 
       
Country of origin, N (%) 
(Canada) 
 
 43 (97.7%)  87 (96.7%) 134 (91.3%) 16 (100%) 0.2291 
Race, N (%) 
(White Caucasian) 
 
 43 (97.7%)  88 (97.8%) 142 (89.3%) 15 (93.8%) 0.5402 
Education, N (%) 
 None/Elementary 
 High School/Diploma 
 College/University/+ 
   
 1 (2.3%) 
  21 (47.7%) 
  22 (50.0%) 
 
  
4 (4.4%) 
 25 (27.8%) 
 61 (67.8%) 
  
 7 (4.7%) 
  35 (23.0%) 
108 (72.3%) 
 
 0 (0.0%) 
  5 (33.3%) 
11 (66.7%) 
 
0.1034 
Children (None), N (%) 
 
32 (72.7%) 
 
83 (92.2%) 139 (92.7%) 13 (81.3%) 0.0026 
 
*: t test for continuous variable (age) and chi square test for all categorical variables 
    
The findings from Table 11 showed that the average age was different across the study sites 
(p=0.0044) with the lowest mean age of 41.8 years at the NBSJ site, and the highest mean age of 
48.7 years in NSH. We also found a significant difference in the proportion of the HIV-positive 
participants with children across the study sites (p=0.0026) with the highest in St. John’s, NL 
(27.3%) and the lowest in Halifax, NS (7.3%).  
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Table 12: Distribution of the Risk Factors for HPV associated Malignancy by Provinces 
(N=300) 
RISK FACTOR NLSJ 
N=44  
(34 males) 
NBM 
N=90 
(85 males) 
NSH 
N=150 
(142 males) 
NBSJ 
N=16 
(14 males) 
P 
value* 
 
HPV in Anal 
Specimen (Positive) 
N (%) 
 
  35/44 
(79.5%) 
 
 
77/90 
(85.6%) 
 
  133/150 
   (88.7%) 
 
     15/16 
     (93.8%) 
 
0.1001 
 
Smokers (yes), N (%) 
 
 
  22/44 
 (50%) 
 
38/90 
 (42.2%) 
 
  65/150 
 (43.3%) 
 
      5/16 
    (31.3%) 
 
0.6165 
 
Number of Male 
Partners/year** N (%) 
 0 
 1-2 
 ≥3 
 
 
 
  23 (52.2%) 
12 (27.3%) 
    9 (20.5%) 
 
 
 
   37 (41.1%) 
   32 (35.6%) 
   21 (23.3%) 
 
 
 
     44 (29.3%) 
     66 (44.0%) 
     40 (26.7%) 
 
 
 
       3 (18.7%) 
     10 (62.5%) 
       3 (18.8%) 
 
 
 
0.1595 
 
Number of Female *** 
Partners/year, N (%) 
 0            
 ≥1 
 
 
 
29 (85.3%) 
  5 (14.7%) 
 
 
 
73 (85.3%) 
    12 (14.7%) 
 
 
 
130 (91.5%) 
     12 (8.5%) 
 
 
 
12 (85.7%) 
  2 (14.3%) 
 
 
 
0.4687 
 
History of 
Unprotected Anal Sex 
(yes), N (%) 
 
 
 
  6 (13.6%) 
 
 
18 (20.0%) 
 
 
  29 (19.3%) 
 
 
       2 (12.5%) 
 
 
0.7835 
 
History of 
Unprotected Oral Sex 
(yes), N (%) 
 
 
 
  12 (27.3%) 
 
 
   50 (55.6%) 
 
 
71 (47.3%) 
 
 
12 (75.0%) 
 
 
0.0025 
History of 
Unprotected   Vaginal 
Sex**** (yes), N (%) 
    
    3 (30.0%) 
      
 
    1 (20.0%) 
 
 
 3 (37.5%) 
 
 
 1 (50.0%) 
 
 
 1.000 
 
 
    History of Anal Pap 
(yes)**, N (%) 
 
3 (6.8%) 
  
   10 (11.1%) 
   
      14 (9.3%) 
        
        6 (37.5%) 
 
0.0195 
 
       *: t test for continuous variables and chi square test for categorical variables 
    **: Denominator is entire cohort 
  ***: Denominator is number of males 
****: Denominator is number of females                                                                                          
 
 
 
 
 
                                                                                                                                                                59                                                                                                                                                                                                                                                                                        
 
 
The findings from Table 12 showed that there was a significant difference in the rates of reported 
unprotected oral sex (p=0.0025) and in the rates of anal Pap test (p=0.0195) among the four 
study sites with their highest rates at the NBSJ (75.0% & 37.5% respectively). The distribution 
of other risk factors for HPV associate malignancy did not differ significantly across the study 
sites. 
 
Table 13: Distribution of Risk Factors for HPV Infection by Provinces 
RISK FACTOR NLSJ 
(St. John’s) 
N=44 
NBM 
(Moncton) 
N=90 
NSH 
(Halifax) 
N=150 
NBSJ 
(Saint John) 
N=16 
P value* 
HEP B (yes), N (%) 
 
   7 (15.9%) 8 (8.9%) 15 (10.0%) 3 (18.8%) 0.4456 
HEP C (yes), N (%) 
 
   4 (9.1%) 
 
10 (11.1%) 15 (10.0%) 3 (18.8%) 0.7492 
ANOGENITAL WARTS 
(yes), N (%) 
 
 18 (40.9%) 33 (36.7%) 53 (35.3%) 6 (37.5%) 0.9508 
CHLAMYDIA (yes), N (%) 
 
   2 (4.5%) 10 (11.1%)     14 (9.3%) 3 (18.8%) 0.3767 
GONORRHEA (yes), N (%) 
 
   7 (15.9%) 20 (22.2%)     40 (26.7%) 5 (31.3%) 0.4710 
SYPHILIS (yes), N (%) 
 
   2 (4.5%) 3 (3.3%)     26 (17.3%)     1 (6.3%) 0.0032 
GENITAL HERPES  
(HHV 2), (yes), N (%) 
 
   6 (13.6%)  12 (13.3%)     27 (18.0 %) 2 (12.5%) 0.7487 
Total Number of STIs/person 
Mean (SD), (min, max) 
 
1.1(1.2) 
0-4 
1.0 (1.1) 
0-4 
1.3 (1.3) 
0-6 
1.4 (1.5) 
0-4 
0.3863 
 
*: t test for continuous variable (# of STIs) and chi square test for all categorical variables 
 
The findings from Table 13 showed that the distribution of history of STIs among HIV-positive 
participants did not differ significantly across the study sites. However, the proportion of 
previously contracted Syphilis was significantly different among the four study sites (p=0.0032) 
with the highest at the NSH site (17.3%) and the lowest at the NBM site (3.3%).       
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Table 14: Participants’ Knowledge of HPV and HPV-associated Conditions  
SURVEY QUESTIONS NLSJ 
(St. John’s) 
N=44 
NBM 
(Moncton) 
N=90 
NSH 
(Halifax) 
N=150 
NBSJ 
(Saint John) 
N=16 
P value* 
HPV doesn’t cause  
Anogenital Warts, N (%) 
    True 
    False** 
    Don’t know 
 
 
 
8 (18.2%) 
   20 (45.5%) 
   16 (36.4%) 
 
 
14 (15.6%) 
37 (41.1%) 
39 (43.3%) 
   
 
9 (6.0%) 
65 (43.3%) 
76 (50.7%) 
 
 
2 (12.5%) 
8 (50.0%) 
6 (37.5%) 
 
 
0.147 
HPV can cause  
Cervical Cancer, N (%) 
 True** 
 False 
 Don’t know  
 
 
 
32 (72.7%) 
1 (2.3%) 
11 (25.0%) 
 
 
68 (75.6%) 
 1 (1.1%) 
 21 (23.3%) 
 
 
97 (64.7%) 
 5 (3.3%) 
48 (32.0%) 
 
 
  12 (75.0%) 
  1 (6.3%) 
    3 (18.8%) 
 
 
0.522 
             HPV Vaccine can lower risk for  
Cancer & Warts, N (%) 
 True** 
 False 
 Don’t know 
 
  
 
30 (68.2%) 
      0 (0.0%) 
    14 (31.8%) 
  
 
40 (44.4%) 
  9 (10.0%) 
41 (45.6%) 
  
 
55 (36.7%) 
9 (6.0%) 
  86 (57.3%) 
  
 
 10 (62.5%) 
 1 (6.3%) 
   5 (31.3%) 
 
 
0.003 
      Importance of PAP test for  
           Women with HPV Vaccination 
 (yes), N (%) 
 
 
 
44 (100%) 
 
 
80 (88.9%) 
 
 
120 (80.0%) 
 
 
14 (87.5%) 
 
 
0.069 
Importance of Safer Sex  
           for those with HPV Vaccination  
(yes), N (%) 
 
 
 
44 (100%) 
 
 
83 (92.2%) 
 
 
 131 (87.3%) 
 
 
  14 (87.5%) 
 
 
0.114 
 
    *: Chi square test for all categorical variables 
  **: Correct answers are italicised. 
 
 
Our findings from Table 14 showed that the levels of knowledge about HPV and HPV-associated 
conditions did not differ significantly among the study sites. However, the proportion of the 
participants who checked True in the questionnaire about HPV vaccine and its impact on the risk 
of cervical cancer and warts was significantly different among the study sites (p=0.003) with     
the highest at the NLSJ (68.2%).                                                                                                   61                                                                                                                                                                                         
 
 
3.1.3. Results from the Analyses of the Laboratory Tests 
In this prospective cohort study, the annual measurements of CD4 T cell counts and 
plasma HIV RNA load levels were analyzed from the baseline and three consecutive years of 
follow up. The 12- and 9-item Clinical Questionnaires (Appendix D & E) included only snap-
shot annual measurements of both HIV markers at the time of appointment with a treating 
physician, and did not provide data related to these parameters’ mean, median, nadir, and range 
measurements during the whole year of observation. For research purposes, the CD4 T cell count 
was traditionally categorized at the 200 cells/mL being the cut-off. These two categories were: 
patients with CD4 count < 200 cells/mL and patients with CD4 count ≥200 cells/mL. The 
following references were used to justify this categorization: 
According to the US DHHS, CD4 T count < 200 cells/uL in HIV-positive adults is the AIDS 
defining illness.  Both HIV RNA load > 100,000 copies/mL and CD4 count < 200 cells/uL 
associated with an increased risk of anal cancer (US Department of Health and Human Services, 
2009).  
There is evidence from different studies on the incidence of oral opportunistic infections in 
adults with HIV/AIDS. Studies showed that among those with CD4 cell count less than 200 
cells/mL, the incidence of oral opportunistic infections [Kaposi’s sarcoma (100%), candidiasis 
(82.2%), linear gingival erythema (70.0%), hairy leukoplakia (66.3%), and others] was strongly 
associated with severe immune suppression. The incidence of these infections was found to be 
significantly correlated to a reduced CD4 cell count, thus serving as a potential clinical marker of 
HIV viremia and progressive HIV disease (OR (95%CI)=3.1 (1.9-4.9);  p<0.001) (Bodhade AS, 
Ganvir SM & Hazarey VK, 2011;  Patton LL, 2000).  
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Plasma HIV RNA viral load was reported by the study sites as categorical data: (0) “Never had 
test” (1) “Undetectable level of serum RNA at ≤50 copies/mL” (2) “Detectable level at >50 
copies/ml” (3) “Unknown.” These categories of serum HIV RNA have already been widely used 
by our co-investigators. In our statistical analyses, serum HIV RNA was always treated as a 
continuous variable. 
Table 15: Important Variables included in the Statistical Analyses 
Name and Type of Variable Statistical Analysis 
Age                                                            Continuous 
                                                                   Categorical 
 
Mean (SD), t-test 
Chi Square 
Gender                                                          Binomial Chi Square 
CD4 T cell count                                      Continuous 
                                                                   Categorical 
 
Mean (SD), Median, Min-Max, t-test 
Chi Square 
Plasma HIV RNA Viral Load                Continuous Mean (SD), Median, Min-Max, t-test 
Number of HPV Genotypes                    Continuous Mean (SD), Median, Min-Max, t-test 
HPV Genotype Individually                        Binomial Chi Square 
Smoking                                                         Binomial Chi Square 
Precancers/Cancer                                        Binomial Chi Square 
Number of Male Partners                        Continuous 
                                                                    Categorical 
           
Mean (SD), Median (IQR) 
Chi Square 
History of STIs                                      Dichotomous Chi Square 
History of Hepatitis C                           Dichotomous Chi Square 
History of Anogenital Warts                Dichotomous Chi Square 
History of Genital Herpes                     Dichotomous         Chi Square 
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The association between the outcome variables (the precancerous lesions and incident cancers) 
and predictors was examined in logistic regression analyses.  
                                                                                                                                                                                                    
The mean, median and min/max values of the laboratory tests were provided. Our findings are 
shown in Tables 16 & 17 and Linear Graphs 1 & 2. 
Table 16: Comparison of the CD4 T cell count Measurements (cells/mL)  
Through the Study Years 
 
Year in the 
 study & N 
Mean CD4 
Count  
Median CD4 
Count 
 
Min CD4 
Count 
 
Max CD4 
Count 
 
Baseline (300) 
 
    366 
 
360 
 
3 
 
     1404 
 
1st F-up (285) 
 
    549 
 
529 
 
10 
 
    1697 
 
2nd F-up (271) 
 
              587 
 
576 
 
15 
 
    1771 
 
3rd F-up (263) 
 
              1,368 
 
583 
 
39 
 
    141,493 
 
                                            Graph 1 
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Table 17: Comparison of the Levels of Plasma HIV RNA (copies/mL) 
Through the Study Years 
 
Year in the  
study & N 
Mean 
 
Median Min  Max 
 
Baseline (300) 
 
     216,397 
 
2,700 
 
50 
 
 7750,000 
 
1 year F-up (285) 
 
        6,484 
 
50 
 
40 
 
1620,000 
 
2 year F-up (271) 
 
        2,567 
 
<50 
 
20 
 
180,000 
 
3 year F-up (263) 
 
          206 
 
<50 
 
0 
 
159,000 
                                                                                                                                           
 
                                                 Graph 2 
 
 
 
Our results showed an improvement in both CD4 cell counts and serum HIV RNA levels 
at different levels of measurements of central tendency (mean, median) and variability (range) of 
the study data.  
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The 12-item Baseline Clinic Questionnaire (Appendix D) included two questions on HIV 
antiretroviral status: (1) “Ever on anti-HIV medication?” (2) “Currently (at the time of entry into 
the current study) on anti-HIV medication?” Analysis of this data showed that of the 300 
baseline participants, 271 (90.3%) were on anti-HIV therapy prior to the study. We may assume 
that at enrolment time, 29 (9.7%) participants were naïve to combined antiretroviral therapy, and 
that their health conditions were improved after initiation of anti-HIV therapy. Moreover, 40 
(13.3%) participants have restarted their ARV treatment at some point during the study years.  
Another explanation of the improvement in the participants’ average health status might be 
related to a more responsible intake and better compliance with anti-HIV drugs. The number of 
participants on anti-HIV therapy varied slightly, from 260 (86.7%) to 232 (88.2%) throughout 
the 4 years of observation. 
Among the 300 participants at the screening year, a total 46 HPV genotypes were detected. Of 
them, 18 (39%) were high-risk (HR: 16, 18, 31, 33, 35, 39, 43, 45, 50, 51, 52, 53, 56, 58, 59, 68, 
73, 82) and 28 (61%) were probable high and low-risk (PHR & LR: 6, 11, 23, 26, 30, 32, 34, 42, 
44, 54, 55, 57, 61, 62, 66, 67, 69, 70, 71, 72, 81, 84, 86, 87, 89, 90, CP108, IS39) types. Of 300 
patients, 246 (82.0%) were “positive” for HPV infection and of these, 156 (63.4%) were infected 
with 3 and more HPV types simultaneously. The highest number of HPV genotypes in one anal 
sample was 15.  The number of HPV genotypes in a single specimen was divided into the two 
large categories: 1) integrating cases with 1 or 2 HPVs and 2) integrating cases with 3 & more 
HPVs. All HPV genotypes were also divided into Low Risk (LR) and High Risk (integrating HR 
& PHR HPVs) categories.  The 2X2 contingency table is shown below:                                                                                                        
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Table 18: Number of HPVs in a Single Specimen stratified by Risk Categories* 
 
Number of HPVs in 
one specimen 
Risk category  
Total 
N (%) 
LR 
N (%) 
HR  
N (%) 
 
1 or 2 HPVs 
 
42 (46.7) 
 
48 (53.3) 
 
  90 (100) 
 
≥ 3 HPVs 
 
59 (37.8) 
 
97 (62.2) 
 
156 (100) 
 
Total 
 
101  
 
145  
 
246 (100) 
 
*: Chi square test, p=0.174 
 
The interpretation of the findings is:  
There was no difference in distribution of HR HPVs between two groups: those patients with 3 
or more HPV genotypes in a single specimen and those with 1 or 2 HPVs in a single specimen 
(62.2% vs. 53.3%, p=0.174). 
 
A total of 625 cytology reports were collected in the screening year from 300 anal, 300 
oropharyngeal, and 25 cervical specimens. The cytology analysis of the specimens showed that 
abnormalities were mostly detected among the anal specimens. 
In this study, we analyzed the distribution of High Risk (HR) HPV genotypes. The most 
frequently observed HR HPV types in all 625 specimens at the screening year were: HPV 16 – 
31.3%; HPV 52 – 15%; HPV 45 – 11.7%; HPV 51 – 11.3%, and HPVs 18 & 59 at 9.3% each.  
The distribution of these and other HPV genotypes at the baseline by both gender and age 
(continuous variable) is shown in Table 19. The differences between groups were examined by 
Chi-Square (χ²) test for gender and by t-test for age. 
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Table 19: Distribution of the Frequently Observed HPV Genotypes by Gender and Age 
among 300 Participants at the Baseline 
 
         HPV 
        TYPE     
  
 
                 GENDER                                      χ²               AGE                                                                      t-test 
  
 
    Males 
   N=275             vs.         
    91.7% 
Females 
  N=25  
    8.3%                     
                                
P*  
Mean (SD)            P  
         
   HPV16 + 
                - 
 
   89 (32.4%) 
186 (67.6%) 
  5 (20.0%) 
20 (80.0%) 
0.386  47.1 (8.4) 
46.9 (9.8) 
0.824   
  HPV18+ 
               - 
 
   25 (9.1%) 
250 (90.9%) 
 
  3 (12.0%) 
22 (88.0%) 
0.716  43.4 (8.4) 
47.3 (9.4) 
       0.035   
  HPV31+ 
              - 
 
   17 (6.2%) 
258 (93.8%)     
 
      2 (8.0%) 
    23 (92.0%) 
0.665  48.6 (9.5) 
46.9 (9.3) 
 
0.421   
  HPV35+ 
              - 
 
   20 (7.3%) 
255 (92.7%) 
 
      3 (12.0%) 
    22 (88.0%) 
0.422  45.4 (8.4) 
47.1 (9.4) 
0.416   
  HPV39+ 
              - 
 
   24 (8.7%) 
251 (91.3%) 
 
  1 (4.0%)  
 24 (96.0%) 
0.707  45.7 (8.2) 
47.1 (9.4) 
0.475   
  HPV45+ 
              - 
 
   33 (12.0%) 
242 (88.0%) 
 
  2 (8.0%)  
  23 (92.0%) 
0.751  45.8 (8.3) 
47.1 (9.5) 
0.447   
  HPV51+ 
              - 
 
   31 (11.3%) 
244 (88.7%) 
 
  3 (12.0%) 
22 (88.0%) 
1.000  43.8 (7.5) 
47.4 (9.5) 
0.037   
  HPV52+ 
              - 
   39 (14.2%) 
236 (85.8%) 
 
 
   6 (24.0%)  
19 (76.0%) 
0.236  49.3 (8.2) 
46.5 (9.5) 
       0.064   
  HPV53+ 
              - 
 
   23 (8.4%) 
252 (91.6%) 
 
  2 (8.0%)  
23 (92.0%) 
1.000  47.6 (8.2) 
46.9 (9.0) 
        0.738   
  HPV56+ 
              - 
 
   17 (6.2%) 
258 (93.8%) 
 
 
  2 (8.0%)  
  23 (92.0%) 
0.665    51.6 (10.7) 
46.6 (9.2) 
        0.024   
  HPV59+ 
              - 
 
   27 (9.8%) 
248 (90.2%) 
 
 1 (4.0%)   
    24 (96.0%) 
  
0.489 
 44.0 (8.4) 
47.3 (9.4) 
        0.075  
  HPV62+ 
              - 
 
   23 (8.4%) 
252 (91.6%) 
 1 (4.0%)   
    24 (96.0%) 
  
0.705 
   52.7 (10.8) 
46.5 (9.1) 
        0.002   
 
*: Fisher Exact p-value when the expected count of cell was less than 5 
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The study findings from Table 19 showed that at the baseline, the distribution of HPV-positive 
genotypes did not differ significantly between males and females. The age distribution between 
HPV-positive and HPV-negative participants also did not differ significantly. However, the 
mean age of HPV 18 and HPV 51 positive participants was significantly lower than the mean age 
of participants negative to those HPVs (43.4 vs. 47.3; p=0.035 & 43.8 vs. 47.4; p=0.037). The 
mean age of HPV 56 and HPV 62 positive participants was significantly higher than the mean 
age of participants negative to those HPV types (51.6 vs. 46.6; p=0.024 & 52.7 vs. 46.5; 
p=0.002). 
At the baseline, the mean (SD) age in the study sample was 46.9 (9.3) years, with the 
following distribution by age categories: 25-39 years of age – 62 (20.7%), 40-59 years of age – 
209 (69.7%) and 60 years and older – 29 (9.6%). Over the four years of observation, the study 
population aged appropriately, skewing towards the middle and older age categories. The mean 
(SD) age at the study end was 51.3 (9.1), with the following distribution by the age categories: 
25-39 years of age – 34 (12.9%), 40-59 years of age – 187 (71.1%) and 60 years and older – 42 
(16.0%).   
At the study end, the most frequently observed HR HPV genotypes were: HPV 16 – 
38.8%; HPV 45 – 19.8%; HPV 52 – 19.4% and HPV 18 – 16.7%. Their distribution was 
stratified by gender and age and is displayed in Table 20. The Chi Square test was carried out for 
gender and t-test for age.        
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Table 20: Distribution of the Frequently Observed HPV Genotypes by Gender and Age 
among 263 Participants at the Study End 
           HPV  
           TYPE 
 
 
 
 GENDER       χ² AGE 
 
 
    t-test   
        Male 
     N=245            vs.     
     93.2% 
  Female       
N=18 
 6.8% 
        P*  Mean (SD)         P 
 
         HPV16+ 
                      - 
 
    
  96 (39.2%) 
149 (60.8%) 
   
  6 (33.3%) 
12 (66.7%) 
 
 
0.803 
  
47.2 (8.6) 
47.2 (9.5) 
           
  0.963  
 
         HPV18+ 
                      - 
 
   42 (17.1%) 
203 (82.9%) 
  2 (11.1%) 
16 (88.9%) 
0.746  44.4 (8.7) 
47.8 (9.2) 
  0.023   
         HPV31+ 
                      -  
 
   21 (8.6%) 
224 (91.4%) 
  2 (11.1%) 
16 (88.9%) 
0.663  47.4 (8.7) 
47.2 (9.2) 
  0.939   
         HPV33+ 
                      - 
  
   20 (8.2%) 
225 (91.8%) 
  3 (16.7%) 
15 (83.3%) 
0.200  46.7 (10.3) 
47.3 (9.0) 
  0.779   
         HPV35+ 
                      - 
 
   32 (13.1%) 
213 (86.9%) 
  3 (16.7%) 
15 (83.3%) 
0.717  47.2 (8.6) 
47.2 (9.2) 
  0.979   
         HPV39+ 
                      - 
 
   29 (11.8%) 
216 (88.2%) 
  3 (16.7%) 
15 (83.3%) 
0.467  48.4 (8.5) 
47.1 (9.2) 
  0.443   
         HPV45+ 
                      - 
 
   50 (20.4%) 
195 (79.6%) 
  2 (11.1%) 
16 (88.9%) 
0.540  45.8 (7.9) 
47.6 (9.4) 
  0.224   
         HPV51+ 
                      - 
 
   40 (16.3%) 
205 (83.7%) 
  2 (11.1%) 
16 (88.9%) 
0.747  43.9 (8.4) 
47.9 (9.2) 
  0.009   
         HPV52+ 
                      - 
 
   49 (20.0%) 
196 (80.0%) 
  2 (11.1%) 
16 (88.9%) 
0.539  48.7 (8.3) 
46.8 (9.3) 
  0.188   
         HPV53+ 
                      - 
 
   25 (10.2%) 
220 (89.8%) 
  3 (16.7%) 
15 (83.3%) 
0.420  49.1 (12.5) 
47.0 (8.7) 
  0.246   
         HPV56+ 
                      - 
 
   25 (10.2%) 
220 (89.8%) 
  2 (11.1%) 
16 (88.9%) 
1.000  50.0 (9.4) 
46.9 (9.1) 
  0.090   
         HPV59+ 
                      - 
 
   32 (13.1%) 
213 (86.9%) 
  1 (5.6%) 
17 (94.4%) 
0.709  44.9 (8.8) 
47.5 (9.2) 
  0.141   
         HPV62+ 
                      - 
 
   31 (12.7%) 
214 (87.3%) 
  1 (5.6%) 
17 (94.4%) 
0.707  51.4 (11.5) 
46.8 (8.8) 
  0.014   
 
*: Fisher Exact p-value when the expected count of cell was less than 5 
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At the study end, the distribution of HPV-positive genotypes did not differ significantly between 
males and females. Neither did the age distribution between HPV-positive and HPV-negative 
participants. However, the mean age of HPV 62 positive participants was significantly higher 
than the mean age of participants negative to HPV 62 genotype (51.4 vs. 46.8; p=0.014). The 
mean age of HPV 18 positive participants was significantly lower than the mean age of 
participants negative to HPV 18 genotype (44.4 vs. 47.8; p=0.023). 
    In summary, the most frequently observed HR HPV genotypes were mainly distributed among 
participants in the middle-age group from 40 to 59 years of age.  Throughout the study, infection 
with HPV 18 was more frequently observed among participants with lower mean age, while 
HPV 62 was more frequently observed among participants with higher mean age. 
We had an opportunity to compare results from two different PCR assays used during the 
screening year only. Reliability of data collection is of overall confidence in research study’s 
accuracy. The importance of technologists in a clinical laboratory having a high degree of 
consistency when evaluating samples is an important factor in the quality of healthcare and 
clinical research studies (McHugh ML, 2012). The Kappa statistics are used to test interrater 
reliability. Kappa ranges from -1 to 1. As with all correlation statistics, the k is a standardized 
value and thus is interpreted the same across multiple studies (Marston L., 2010). It was 
suggested the kappa results be interpreted as follows: value ≤0 – as no agreement; 0.01-0.20 – as 
none to slight; 0.21-0.40 – as fair; 0.41-0.60 – as moderate; 0.61-0.80 – as substantial; and 0.81-
1.00 – as almost perfect agreement. Many texts recommend 80% agreement as the minimum 
acceptable interrater agreement. The SAS Freq. procedure was used to calculate the k coefficient 
between two PCR assays: Luminex and Linear Array.       
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Graphs 3 & 4: HPV Genotypes Detected in the Anal Samples by  
Luminex vs. Linear Array Assays 
 
 
 
The dark columns are HR HPV types                                         X axis – HPV genotypes 
The light columns are LR HPV types                                          Y axis – Number of HPV+ cases 
 
The Kappa statistics to test interrater agreement in detection of HPV16 and HPV18 in anal specimens 
showed strong agreement between Luminex and Linear Array PCR assays: 
HPV16: k=0.81, 95%CI (0.73-0.89), p<0.001; HPV18: k=0.90, 95%CI (0.81-0.99), p<0.001 
The PCR assays are costly and time-consuming. Due to the strong agreement between two tested assays, 
we decided to use a single PCR - Luminex®-Based Genotyping Assay for the HPV DNA and Genotyping 
analysis during the follow-up years.                                                                                                    72 
 
 
The total number of gathered specimens during the study years was 2416 (including 92 
samples from 46 male patients that were originally enrolled at the baseline and were later 
excluded from the study due to the project’s financial issues), and from them, 2324 specimens 
were tested for abnormalities and included in the final analysis (Table 21). 
Table 21: Number of Patients and Specimens throughout the Study 
 Baseline 1
st
 Year F-up 2
nd
 Year F-
up 
3
rd
 Year F-
up 
Total 
Number of 
Patients 
300 285 271 263  
Number of 
Specimens 
625 595 560 544 2324 
 
During the study, 2324 specimens were analysed in total. Of them, 1119 were anal specimens, 
1119 oropharyngeal specimens and 86 cervical Pap smears. Of the unsatisfactory or inconclusive 
specimens reported by the cytopathology laboratory, all were anal Pap smears: 
Baseline: 69 unsatisfactory, of them 28 were repeated within 3 months 
First follow-up: 14 unsatisfactory, 6 were repeated within 3 months 
Second follow-up: 10 unsatisfactory, 7 were repeated within 3 months 
Third follow-up: 21 unsatisfactory, 15 were repeated within 3 months 
Definition by the TBS, 2001: Unsatisfactory specimen means that the laboratory has been unable 
to come to a firm conclusion on the basis of the specimen provided (e.g., not all cell divisions are 
collected, obscuring blood, etc.).                                                                                                   73 
 
 
There were 69 anal specimens at baseline that were reported as unsatisfactory for evaluation. A 
literature review and on-line discussion with the study PI and co-investigators was initiated by 
author. It was decided to switch from cotton swabs to Dacron swabs (NYS Guidelines 
recommendations on anal pap smears). As a result, the proportion of inconclusive anal 
specimens was reduced. No incidence of inconclusive results was reported from the National 
Microbiology Laboratory about PCR tests on HPV DNA and HPV genotyping.                                                                                                                                                                                                                                                                                                            
The type and number of the detected cytological abnormalities varied from year to year, 
and are presented below in Table 22 with calculated prevalence (%). 
Prevalence is the number of individuals identified as cases during a specified period of time, 
divided by the total number of people in that population (Principals of Epidemiology in Public 
Health Practice, CDC, 2012).  
In our study, no cancer cases were diagnosed at the baseline. All cancer cases were diagnosed 
during the follow-up years and treated in the final analysis as incident cases. 
The case definition of precancerous lesion is based on cytological abnormality. There were 
precancerous lesions detected at the study baseline and during the follow-up years (Table 22). 
However, the time of occurrence of any particular abnormality is questionable, and a cut-point in 
time to differentiate the prevalent and incident cases is not clear. Development of a precancerous 
lesion is influenced by factors such as a long viral latency, high rate of viral clearance and 
reinfection, transient manifestation of productive viral infection, and persistent HPV exposure. 
Thus, we treated all precancerous lesions as prevalent cases. 
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Table 22: Prevalence of Cytological Abnormalities in the Study Sample by Type, Body Site 
and Year of Observation 
       Body Site 
   
Type of 
Cytological 
Abnormality 
  Baseline 
  N=300 
1
st
 year  
F-up 
N=285 
2
nd
 year  
F-up 
N=271 
3
rd
 year 
F-up 
N=263 
 
Prevalence 
(%) 
 
     ANUS 
     (denominator is 
     entire cohort) 
 
ASC-US 
LSIL 
HSIL 
 
  100 (56.1%) 
       73 (49.0%) 
        9 (40.9%) 
 
  29 (16.3%) 
36 (24.2%) 
    4 (18.2%) 
 
27 (15.2%) 
19 (12.8%) 
  4 (18.2%) 
 
22 (12.4%) 
21 (14.0%) 
  5 (22.7%) 
 
178/300=59.3 
149/300=4 9.7 
  22/300=7.3 
 
 
     MOUTH 
(denominator is        
number of males) 
 
 ASC-US 
 LSIL 
 
         4 (66.6%) 
         1 (16.7%) 
 
           - 
           - 
 
  1 (16.7%) 
       - 
 
  1 (16.7%) 
       - 
 
    6/275=2.2 
    1/275=0.4 
 
     CERVIX 
(denominator is    
number of females) 
 
ASC-US 
LSIL 
HSIL 
 
       1 (25.0%) 
      2 (8.0%) 
      1 (4.0%) 
    
  2 (50.0%) 
          - 
   
  1 (25.0%) 
       - 
 
       - 
       - 
 
    4/25=16 
    2/25=8 
    1/25=4 
 
All cytology reports were sent back to the study co-investigators. They in turn, referred these 
patients to the specialists (gastroenterology surgeons, gynecologists or ENT specialists) for 
further investigation and/or appropriate treatment with follow-up observations. The results from 
the histology readings throughout the years were accumulated and analyzed when the study was 
completed. Table 23 demonstrates precancerous lesions and cancers among the 263 study 
patients included in this analysis. The cases with ASC-US (TBS) or Atypia (CIN) were excluded 
from the analysis, as cytological changes that might have reversed to the cells’ normal status. 
     Thirty-one precancerous cases were confirmed by histopathology analyses. Of them, 29 anal 
precancers were diagnosed among the study males. Eight incident cancer cases were diagnosed 
and all of them among the study males, including six anal and two oral cancers. 
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Table 23: Precancerous Lesions and Incident Cancers by Body Site 
  
Body Site Precancerous Lesions 
 
Cancer 
       ANUS  AIN I – 20  
AIN II – 5  
 AIN III – 4 
Adenocarcinoma – 1 
               Invasive Cancer – 3  
 Rectal SCC in situ – 1 
               Rectal SCC – 1 
 
  OROPHARYX -               Throat Cancer – 1  
              Tongue Cancer – 1  
     CERVIX    VaIN II (Vaginal HSIL) – 1 
VIN II (Vulvar HSIL) – 1   
- 
 
In summary, in the screening year, the prevalence of HPV-positive cases in the study 
population was 82.0% (246/300); of which, the prevalence of cases with high-risk (HR) HPV 
genotypes was 45.9% (113/246). During the follow-up years, the number of the detected HPV 
types varied. At the end of the study, the total number of the detected HPV genotypes among 263 
participants increased to 50 (Graph 5), with their following distribution: the total number of 
patients positive for HPV infection was 227 (86.3%) and of them, 143 (63.0%) were infected by 
HR HPV genotypes. Of these 227 participants, 200 (88.1%) had HPV infection at one body site 
(mostly anus) and 27 (11.9%) patients had HPV infection at two body sites simultaneously 
(anus/cervix or anus/oropharynx). During the study years, the prevalence of HPV-positive 
patients increased by 4.3% (from 82.0% to 86.3%) and the prevalence of cases with the HR HPV 
genotypes increased by 17.1% (from 45.9% to 63.0%).            
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Graph 5: Distribution of the 50 HPV Genotypes among the Study Population (N=263) 
The dark columns are HR HPV genotypes                           X axis – HPV genotypes 
The light columns are LR HPVs                                            Y axis – Number of patients (cases) 
The white columns are Unknown Effect HPVs 
 
 
 Our further analysis showed that from those 50 genotypes, 8 (16%) were significantly associated 
with the histologically-confirmed 31 (11.8%) cases of precancerous lesions in both males and 
females, and 8 (3.3%) cases of newly diagnosed cancers among the 245 male participants. These 
important Low Risk, High Risk and Unknown Effect (UE) HPV genotypes were 6, 11, 16, 18, 
45, 52, 69, & 74. From those 8 important HPV genotypes, 7 HPV genotypes were significantly 
associated with the precancerous lesions (HPV 39 was at borderline significance with p=0.0564) 
and 2 HR HPV genotypes (16 & 52) were in significant relationship with the cancer cases in 
univariate logistic regression analysis (Tables 24 & 25).                                                                                                                                                                                                      
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Table 24: Seven HPV Genotypes Significantly Associated with Precancerous Lesions 
(N=263) 
 
HPV Genotype 
N (%) 
Precancerous Cases 
N=31 
Proportion of Precancer Cases 
within HPV(+) and HPV(-) 
Cases 
Univariate  
Logistic Regression 
 
OR (95%CI), p 
                                                                       
HPV6:     Posit in 58 (22.1%) 
                  Negat in 205 (77.9%) 
16/58 (27.6%) 
15/205 (7.3%) 
 
 
   4.5 (2.0 – 10.3) , 0.0004 
    1 
HPV11:   Posit in 43 (16.3%) 
                  Negat in 220 (83.7%) 
14/43 (32.6%) 
17/220 (7.7%) 
 
   6.1 (2.6 – 14.2), <0.0001 
    1 
HPV16:   Posit in 102 (38.8%) 
                  Negat in 161 (61.2%) 
28/102 (27.5%)                  
  3/161 (1.9%) 
 
   6.3 (2.5 – 15.6), <0.0001 
    1 
HPV18:   Posit in 44 (16.7%) 
                  Negat in 219 (83.3%) 
10/44 (22.7%) 
21/219 (9.6%) 
 
 
3.4 (1.4– 8.3), 0.0073 
    1 
 
HPV45:   Posit in 52 (19.8%) 
                  Negat in 211 (80.2%) 
11/52 (21.2%) 
20/211 (9.5%) 
 
   2.7 (1.1 – 6.3), 0.0227 
    1 
HPV69:   Posit in 12 (4.6%) 
                  Negat in 251 (95.4%) 
  4/12 (33.3%) 
27/251 (10.8%) 
 
   6.1 (1.6 – 23.4), 0.0077 
    1 
HPV74:   Posit in 18 (6.8%) 
                  Negat in 245 (93.2%) 
 10/18 (55.6%) 
 21/245 (8.6%) 
   6.9 (2.0 – 23.4), 0.0021 
    1 
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Table 25: Two HR HPV Genotypes Significantly Associated with Cancer Cases among  
245 Study Males 
 
HPV Genotype 
N (%) 
Cancer Cases 
N=8 
Proportion of Cancer 
Cases within HPV(+) and    
HPV(-) Cases 
             Univariate 
        Logistic Regression 
 
          OR (95%CI), p 
 
 
HPV16:   Posit in 96 (39.2%) 
                  Negat in 149 (60.8%) 
 
         
        7/96 (7.3%) 
        1/149 (0.7%) 
     
11.6 (1.4-96.2), 0.0227 
       1 
HPV52:   Posit in 49 (20.0%) 
                  Negat in 196 (80.0%) 
     6/49 (12.2%) 
     2/196 (1.0%) 
     13.5 (2.6-69.4), 0.0018 
       1  
 
 
                                                                                                                                            
Our findings from Tables 24 & 25 showed that: 
The proportions of precancerous lesions were significantly higher among participants who were 
positive to the following seven HPV genotypes: 6, 11, 16, 18, 45, 69 & 74 than among 
participants negative to the same HPV genotypes.  
The proportions of cancers were significantly higher among patients who were positive to HPV 
16 and/or HPV 52 as compared to those who were negative to these two HR HPVs. 
 
     As part of additional analyses, both the Chi Square test and t-test were conducted to find out 
how well the study outcomes and patient’s characteristics are related. Analysis of cancer did not 
show any significance (the sample of 8 cases being too small). The t-test of the association 
between mean values of the continuous variables such as CD4 T cell count and HIV RNA viral 
load and the precancers did not show any significance as well. The Chi-Square tests (χ²) between 
the categorical variables such as CD4 T cell count categories, smoking status, history of 
anogenital warts and HHV-2 and precancerous lesions showed significant association (Chart 2).       
                                                                                                                                                        79                                                                                                                              
 
 
CHART 2: Association between Precancerous Lesions and Predictor Variables 
 
 
 
 
 
 
 
 
 
 
 
*: Chi-square (χ²) test   
The interpretation of these findings is: 
The proportion of precancerous lesions among the study  participants with CD4 cell count less 
than 200 cells/mL was more than 2 times higher than proportion of precursor lesions among 
those with CD4 cell count equal to or greater than 200 cells/mL (18.9% vs. 9.0%, p=0.024).  
The proportion of precancerous lesions was almost 3 times higher among smokers than 
proportion of precancerous lesions among non-smokers (18.9% vs. 6.6%, p=0.002). 
The proportion of precancers was 2.8 times higher among patients with a history of ano-genital 
warts and 2.6 times higher among patients with a history of genital herpes than proportions of 
precancerous lesions among those without history of these sexually transmitted infections 
(20.0% vs. 7.1%, p=0.002; and 23.7% vs. 9.0%, p=0.024 respectively).                                                                                                                  
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Proportion of Precancerous Lesions (95%CI) * N=31) 
1. CD4 cells/mL 
 
< 200: 18.9% (0.089-0.260) 
 
≥ 200:   9.0% (0.045-0.124)  
P=0.024 
3. History of or Current Anal 
& Genital Warts (HPV) 
 
YES: 20.0% (0.11-0.27) 
 
  NO:   7.1% (0.028-0.103) 
P=0.002 
4. History of or Current 
Genital Herpes (HHV-2) 
 
YES: 23.7% (0.102-0.372) 
 
  NO:   9.0% (0.052-0.126) 
P=0.024 
2.   Smoking % (95%CI) 
 
YES: 18.9% (0.101-0.241)  
 
  NO:   6.6% (0.026-0.105) 
P=0.002 
 
 
 
 
3.1.4. Results from Logistic Regression Analyses 
The study results showed zero cancer cases among the study females. Therefore, the author 
excluded females from the Logistic Regression analyses and focused only on 245 male subjects. 
 
3.1.4. IA:  The Results from Univariate Logistic Regression Analysis of Precancerous 
Lesions 
 
Univariate analysis was carried out to evaluate association between precancers and each of the 
risk factors individually. Prevalence of precancers (yes vs. no) was used in the logistic regression 
models. The following predictor (independent) variables were included in the univariate logistic 
regression analysis of precancers (Table 26): (1) Age (continuous) (2) Gender (dichotomous) (3) 
Two education categories with “high school” being a cut-off point (4) Two categories of male 
partners (“0” partner vs. “≥1” partners) (5) Smoking (yes vs. no) (6) CD4 T cell count categories 
(<200 vs. ≥200 cells/mL) (7) HIV RNA viral load (continuous) (8) History of unprotected sex: 
anal, oral (yes vs. no) (9)  History of STIs: anogenital warts, genital herpes (yes vs. no). 
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Table 26: Univariate Analysis of Association between Predictors and Precancerous Lesions 
among 245 Study Males 
 
Predictor Variable Mean (SD) values & 
Proportions of 
Precancers 
OR (95%CI) ULRM 
P 
Age, mean (SD)               47.6 (9.1) 1.0 (0.96-1.1) 0.8947 
Education Level, N (%) 
   None/Element/High School Dipl. (74)                            
           Undergrad/Grad/Postgrad (171) 
 
            12/74 (16.2%) 
            17/171 (9.9%) 
 
 
1.8 (0.8-3.9) 
                1 
 
 
0.1666 
Male Partners, N (%) 
                                                ≥1 (145) 
                                                      0 (100)                                                  
Smoking, N (%)                            
                                                  Yes (103) 
                                                   No (142) 
 
             21/145 (14.5%) 
               8/100 (8.0%) 
             
             20/103 (19.4%)              
               9/142 (6.3%) 
             
 
1.9 (0.8-4.6) 
                1 
 
3.6 (1.5-8.2) 
                1 
 
0.1277 
 
0.0028 
CD4 T cell count 
                                   <200 cells/mL (65) 
                                 ≥200 cells/mL (180) 
 
 
             12/65 (18.5%) 
             17/180 (9.4%) 
 
 
2.2 (1.0-4.8) 
                1 
 
0.0580 
Plasma HIV RNA, mean (SD) 206 (701.7) 1.0 (1.0-1.1) 0.6543 
History of Unprotected Anal Sex 
                                              Yes (46) 
                                             No (199) 
History of Unprotected Oral Sex 
                                            Yes (124)                                           
                                             No (121) 
 
               7/46 (15.2%) 
             22/199 (11.1%) 
 
               
             15/124 (12.1%) 
             14/121 (11.6%) 
 
1.4 (0.6-3.6) 
                1 
 
 
1.1 (0.5-2.3) 
                1 
 
0.4330 
 
 
0.8985 
History of Anogenital Warts                                                                     
                                            Yes (88) 
                                           No (157) 
 
             17/88 (19.3%) 
             11/157 (7.6%) 
 
2.9 (1.3-6.4) 
                1 
 
0.0085 
History of Genital Herpes 
                                             Yes (34) 
                                             No (211) 
  
      7/34 (20.6%) 
      22/211 (10.4%) 
 
2.2 (0.9-5.7) 
                1 
 
0.0954 
 
The results from Table 26 showed that the study smokers are 3.6 times more likely to have a 
precancerous lesion than non-smokers (OR=3.6, p=0.0028). The study participants with the 
history of anogenital warts were 3 times more likely to have a precancerous lesion than those 
without history of warts (OR=2.9, p=0.0085). Other predictor variables did not show significant 
association with the precancerous lesions.     
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Seven HPV genotypes (6, 11, 16, 18, 45, 69 & 74) were significantly associated with the 
precancers in univariate regression model (Table 24).   
                                                                                                                                 
3.1.4. IB: The results from Multivariate Logistic Regression Analysis of Precancerous 
Lesions 
 
Multivariate Logistic Regression model was built to identify significant risk factors for 
precancerous lesions after adjusting for other factors. A purposeful selection method was used to 
build our final model. The ensuing analysis answered the following question: Which patient’s 
characteristic and significant HPV genotype were associated with the precancerous lesions after 
adjusting for other factors? (Table 27) 
Table 27: Significant Risk Factors Associated with the Development of Precancerous 
Lesions 
 
Predictor Variable* 
 
OR (95%CI) P value 
                       Smoking                     yes 
                                                            no 
4.9 (1.6-15.9) 
                  1 
         0.0080 
 
              CD4 cell count   <200 cells/mL 
                                          ≥200 cells/mL 
 
 
7.5 (2.1-26.3) 
                  1 
 
         0.0018 
        HPV11             positive 
                                negative  
         3.9 (1.3-12.1) 
          1 
      0.0182 
        HPV16             positive 
                                negative 
34.8 (6.8-177.0) 
          1 
    <0.0001 
       HPV69             positive 
                               negative  
14.6 (1.2-177.0) 
          1 
      0.0350 
       HPV74             positive 
                               negative  
         18.7 (4.1-85.4) 
          1 
      0.0002 
 
*: MLR model included age, smoking, CD4 cell count categories, HPVs 11, 16, 69 & 74  
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The results from Table 27 showed that from risk factors included in the final multivariate 
regression model, smoking, CD4 T cell count and four HPV genotypes were significantly 
associated (p<0.05) with the precancerous lesions. Smokers were 5 times more likely to have a 
precancerous lesion than non-smokers (OR=4.9; p=0.0080) ; Among the study participants those 
with the CD4 T cell count less than 200 cells/mL were 7.5 times more likely to have a  
precancerous lesion than participants with CD4 T cell count ≥200 cells/mL (OR=7.5; p=0.0018); 
Among the study participants those positive to one or more of the four HPV genotypes (11, 16, 
69, 74) were significantly more likely to have a precancerous lesion than participants who were 
negative to these HPV genotypes.                                                                            
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3.1.4. IC: Multivariate Logistic Regression Model of the Interaction between Four 
Significant   HPV Genotypes 
 
The next step in our analysis was to find out:  Which combinations of or interactions between 
those 4 significant HPV genotypes (11, 16, 69, 74) were the most important in their association 
with the precancerous lesions? The multivariate model included main effects and statistically 
significant (p<0.05) interaction terms. 
         Table 28: Interaction of 2 HPV Genotypes in Significant Relationship with the 
Precancerous Lesions 
 
HPV74*HPV16  OR (95%CI) P value 
HPV74 (+)       HPV16 (+) 
                              HPV16 (-)    
8.3 (2.2-30.9) 
                   1 
0.0016 
HPV74 (-)       HPV16 (+) 
                              HPV16 (-)  
 0.4 (0.03-5.46) 
                  1 
0.4813 
 
*: Interaction between HPV genotypes 
                                                              
The interpretation of the findings from the multivariate regression analysis is: 
Among the study patients who were HPV 74 positive,  those  with HPV 16 positive were 8.3 
times more likely to have a precancerous lesion than those HPV 16 negative (OR=8.3, 
p=0.0016). Among the study patients who were HPV74 negative, no such association was 
observed (OR=0.4, p=0.4813). 
We also examined the effect of multiple HPV infections in a single specimen on the risk 
of the precancerous lesions.  The number of HPV genotypes per specimen was treated in the 
model as a continuous variable (mean [SD] = 3.6 [3.1]). 
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Table 29: Effect of Multiple HPV Infections on the Risk of Precancerous Lesions (N=245) 
       Variable* 
 
Multiple HPVs  
In a single specimen 
                                                                                        
              OR (95%CI) 
 
 
1.1 (1.08 – 1.13) 
     P value 
 
 
    <0.0001 
 
*: Variable was treated as continuous in the logistic regression model. 
MLR model included: age, smoking, CD4 T cell count and number of HPV+ types in a specimen. 
 
The interpretation of the finding: The multiplicity of HPV infection in a single specimen is 
significantly associated with the precancerous lesions.  Among the study participants who are 
infected with multiple HPV genotypes, the risk to have a precancerous lesion increases by 10% 
with every one more count of HPV genotype in a single specimen (OR=1.1; p<0.0001).  
 
3.1.4. IIA:  Univariate Logistic Regression Analysis of Cancers 
Univariate analysis was carried out to evaluate the association between each of the risk factors 
and cancer cases. The incident cancer cases (yes vs. no) were used in the logistic regression 
models. The univariate analysis showed that (Table 30) none of the demographic and clinical 
characteristics was significantly associated with the newly developed cancers (8 cases comprise a 
fairly small sample). However, the study participants with the history of Hepatitis C were almost 
6 times more likely to develop cancer than those without history of this blood born viral infection 
(OR=5.86, p=0.0206).                                                                      
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Table 30: Analysis of Association between Predictor Variables and Cancer (ULRM) 
Predictor Variable Mean (SD) values & 
Proportions of 
Cancer 
OR (95%CI) P value* 
Age, mean (SD)      51.3 (9.1)            1.1 (1.0-1.13) 0.2424 
Education Level, N (%) 
    None/Element/High School Dipl.(74) 
           Undergrad/Grad/Postgrad (171) 
 
 4/74 (5.4%) 
 4/171(2.3%) 
 
          2.4 (0.6-9.8) 
          1 
 
0.2280 
 
Male Partners, N (%) 
                                                 0 (100) 
                                               ≥1 (145) 
 
Smoking, N (%)                            
                                                  Yes (103) 
                                                   No (142) 
 
 
              4/100 (4.0%) 
              4/145 (2.8%) 
  
              4/103 (3.9%) 
              4/142 (2.8%) 
           
 
            
          1.5 (0.4-6.0) 
           1 
             
          1.4 (0.3-5.7) 
           1 
 
 
         0.5931 
 
 
         0.6442 
 
CD4 T cell count 
                                <200 cells/mL (65) 
                              ≥200 cells/mL (180) 
 
 
 
   1/65 (1.5%) 
    7/180 (3.9%) 
            
 
          0.4 (0.05-3.2) 
           1 
 
 
       0.3779 
Plasma HIV RNA, mean (SD)      205.6 (701.7)                 1.0 (0.99-1.0) 0.4463 
History of Unprotected Anal Sex 
Yes (46) 
No (199) 
History of Unprotected Oral Sex 
                                          
Yes (124) 
No (121) 
 
              0 (0%) 
              8 (4.0%) 
 
             4/124 (3.2%)                                 
             4/121 (3.3%) 
 
             NA 
  
             
1.0 (0.2-4.0) 
            1 
 
NA 
 
 
0.9719 
History of Hepatitis C 
                                                     Yes (25) 
                                               No (220) 
 
              3 (12.0%) 
              5 (2.3%) 
 
 
           5.86 (1.31-26.20) 
            1 
 
0.0206 
History of Anogenital Warts                                                                     
Yes (88) 
No (157) 
             5 (5.7%) 
             3 (1.9%) 
 
            3.09 (0.72-13.26)            
            1 
                           
  
        0.1286 
     
   
History of Genital Herpes      
                                                     Yes (34)  
                                                    No (211)                                                                                        
 
             1 (2.9%) 
             7 (3.3%) 
 
            0.88 (0.11-7.41) 
            1       
 
0.9088 
 
*: p-value from univariate logistic regression model 
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3.1.4. IIB: Multivariate Logistic Regression Analysis of Cancers 
Multivariate Logistic Regression model was developed in order to identify significant predictors 
of cancer after adjusting for other factors. The incidence of cancer (yes/no) was used in this 
analysis as a binary dependent variable.  
 
Table 31: Predictor Variables Associated with Cancer in Multivariate Logistic Regression 
Model adjusted to other Factors 
 
Predictor Variable*                                    OR (95%CI)                                 p value 
  
       Hepatitis C          
                                      yes                           5.8 (1.07-31.20)                              0.0410 
                                       no                           1 
 
HPV16              positive 
                         negative  
 
                6.3 (0.68-59.5) 
                 1 
                  0.1059 
HPV52              positive 
                         negative 
                7.0 (1.20-40.81) 
                 1 
                  0.0310 
 
 
*: MLR model included age, history of HCV, HPVs 16 & 52      
                                                                                                                                                
 
The results from Table 31 showed that the study participants who had a history of Hepatitis C 
were almost 6 times more likely to have cancer (OR=5.8, p=0.0410) than those without the 
history of Hepatitis C. Among the study participants those positive to HPV 52 were 7 times more 
likely to develop cancer than those negative to HPV 52; among the study participants those 
positive to HPV 16 were 6 times more likely to develop cancer than those negative to HPV 16. 
However, the result did not reach statistically significant level at α<0.05. 
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3.1.4. IIC: Multivariate Logistic Regression Model of the Interaction between Two 
Significant HPV Genotypes 16 & 52 
 
Next, we investigated if there was an interaction between those two HPV genotypes.                                                                                                                                                                                                                                                                                                       
Our results showed that there was no interaction terms between HPV 16 and HPV 52 (p=0.386). 
Each genotype acted individually and was independently associated with incident cancers.  
 
In our study, the prevalence of precancerous lesions and incidence of malignancy varied 
among Atlantic Provinces with the highest numbers in Halifax, Nova Scotia with 15 (48.4%) 
cases of precursor lesions and 5 (62.5%) cancer cases. Two study sites in New Brunswick had 
total 14 precancerous cases, of them 10 (32.3%) in Moncton and 4 (12.9%) in Saint John. There 
was one new cancer case per the abovementioned sites in NB (12.5% each). The lowest numbers 
were observed in St. John’s, NL: two (6.5%) precancerous and one (12.5%) cancer cases (Graph 
6 and Table 32): 
 Graph 6: Precancerous Lesions and Cancers stratified by the Study Site 
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Table 32: Distribution of the Precancerous and Cancer Cases by the Study Site 
 
Study Site, N-%        AINI       AINII      AINIII    CANCER 
 
NLSJ (42 - 16%) 
 
1 
 
1 
 
0 
 
1 
NBM (84 - 32%) 6 3 1 1 
NSH (121 - 46%) 11 1 3 5 
NBSJ (15 - 6%) 2 2 0 1 
Total 20 7 4 8 
 
The proportion of precancerous lesions and cancers was also varying within the age categories 
with their highest numbers (%) among the oldest participants (Graph 7): 
 
Graph 7: Precursor Lesions and Cancers stratified by Age Categories 
 
 
  X axis – Age Categories 
  Y axis – Precancerous Lesions and Cancers (%) 
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The prevalence of precancerous lesions in the study cohort was 31/263 (11.8%), of them 29 
(93.5%) anal cases were diagnosed in men. The distribution of these lesions was different across 
the cohort’s age groups (Graph 7, blue line): 25 – 39 years of age – 4/34 cases (11.8%); 40 – 59 
years of age – 18/187 cases (9.6%); 60 years of age & older – 9/42 cases (21.4%). 
The incidence of cancers was 8/245 (3.3%). The distribution of cancer cases was different across 
the male age categories (Graph 7, red line): 25 – 39 years of age – 0/31 cases (0.0%); 40 – 59 
years of age – 6/173 cases (3.5%); 60 years of age & older – 2/41 cases (4.9%). 
 
3.1.5. Calculation of Incidence Rate (Person-time Rate) and ASIR of Cancer 
       We investigated 300 HIV-infected adults and followed them annually for 3 consecutive 
years to determine the incidence rate of HPV-associated anal and oropharyngeal cancers.    
Incidence Rate (Unadjusted) or Person-time Rate incorporates missing data (Principals of 
Epidemiology in Public Health Practice, CDC, 2012). Incidence Rate of cancer was calculated 
using the ratio of the number of cancer cases to the total time the sample population was at risk 
of HPV-associated cancer:    
       Number of new cancer cases / Time each person was observed, totaled for all persons 
Person-time is an estimate of the actual time-at risk in years that all persons contributed to this 
study. We assumed that the probability of cancer during the study period was constant (one of 
person-time assumptions). We also assumed that participants lost to follow-up were in the study 
for half the year, and thus contribute half of the calendar year to the denominator. The same 
assumption is made for participants diagnosed with cancer. We assumed that they were disease-
free for half the year, and thus contribute to the denominator 1/2 of the calendar year when the 
event happened. The Person Years (PYs) were calculated among 275 males at the study baseline.  
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From 39 participants that were lost to follow up, 7 were females and 2 died but reached the study 
end point and became a case. A total number of males that were lost during the study was 30. 
Age Standardized Incidence Ratio (ASIR) is used to determine if the occurrence of cancer in a 
relatively small population is high or low. To calculate the age-standardized incidence rate, we 
must first calculate the age-specific incidence rates for each age group by dividing the number of 
cancer cases by the respective population, and then multiplying the resulting number by 100,000 
(Principals of Epidemiology in Public Health Practice, CDC, 2012). We used the Canadian male 
population as a reference group to account for age distribution (Stat. Canada 2015). 
                                                                                                                                              
Anal Cancer 
Age group N at baseline 
Loss to Follow-up  
& Cancers Person Years (PYs) 
1st year 2nd year 3rd year 1st year 2nd year 3rd year Total 
25-29 10   1 L   10 9.5 9 28.5 
30-34 13   1 L 1 L 13 12.5 11.5 37 
35-39 23     1 L 23 23 22.5 68.5 
40-44 59 3 L 2 C 3 L 2 L 56.5 52.5 50 159 
45-49 65 4 L 1 C 3 L 63 60.5 58.5 182 
50-54 43 4 L 1 C 1 L 41 38.5 37.5 117 
55-59 34   2 L 2 L 1 C 34 33 30.5 97.5 
60-64 17 1 L   1 C 16.5 16 15.5 48 
65-69 8   1 L   8 7.5 7 22.5 
70-79 3  12L + 2C  8L + 2C 10L + 2C  3 3 3 9 
Total 275 
   
268 256 245 769 
L: Number of Participants Lost to Follow-up 
C: Number of Incident Anal Cancers 
 
95% CI= Adj. Rate ± 1.96*SE =0.005 ± 1.96*0.0024 = (0.0003-0.0097) 
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Age group 
N of 
Cases (di) 
PYs 
 (pi) 
Rate 
 (di/pi) 
Standard Pop 
(wi) 
Expected cases 
(wi*di/pi) 
Proportion     
(wi/sum(wi))  Variance  
25 to 29 0 28.5 0 2517100 0 0.095511843                    0 
30 to 34 0 37 0 2530200 0 0.096008925                    0 
35 to 39 0 68.5 0 2456100 0 0.093197186                    0 
40 to 44 2 159 0.01257862 2345400 29501.88679 0.088996653  6.18708E-07 
45 to 49 1 182 0.00549451 2415200 13270.32967 0.091645228  2.52165E-07 
50 to 54 1 117 0.00854701 2711300 23173.50427 0.102880799  7.666E-07 
55 to 59 1 97.5 0.01025641 2653200 27212.30769 0.100676183  1.05528E-06 
60 to 64 1 48 0.02083333 2300100 47918.75 0.087277736  3.23729E-06 
65 to 69 0 22.5 0 1975700 0 0.074968316                     0 
70 to 79 0 9 0 4449500 0 0.168837132                     0 
 
6 769 0.00780234 26353800 141076.7784 1  5.93004E-06 
   
0.00780234 Adj. Rate= 0.005353185 SE= 0.002435167 
pi : the number of PYs in age group i in the study population 
Ri: the cancer rate in age group i in the study population  
wi: the number of persons in age group i in the standard population 
 
   Unadjusted Incidence Rate (per 100,000): 780.234 
   Adjusted Incidence Rate (per 100,000):      535.319 95%CI (30-970) 
 
Oral Cancer 
 
        
Age group 
N at 
baseline 
Loss to Follow-up & Cancer Person Years (PYs) 
1st year 2nd year 3rd year 1st year 2nd year 3rd year Total 
25-29 10   1 L   10 9.5 9 28.5 
30-34 13   1 L 1 L 13 12.5 11.5 37 
35-39 23     1 L 23 23 22.5 68.5 
40-44 59 3 L 3 L 2 L 57.5 54.5 52 164 
45-49 65 4 L   3 L 63 61 59.5 183.5 
50-54 43 4 L 1 C   1 L 40.5 38 37.5 116 
55-59 34 1 C 2 L 2 L 33.5 32 30 95.5 
60-64 17 1 L     16.5 16 16 48.5 
65-69 8   1 L   8 7.5 7 22.5 
70-79 3  12L + 2C  8L + 0C 10L + 0C  3 3 3 9 
Total 275 
   
268 257 248 773 
L: Number of Participants Lost to Follow-up 
C: Number of Incident Oropharyngeal Cancers 
 
95% CI= Adj. Rate ± 1.96*SE =0.005 ± 1.96*0.0024 = (0.0003-0.0097)                                                  93                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
 
 
Age group 
N of Cases 
(di) 
PYs 
 (pi) 
Rate 
Ri=(di/pi) 
Standard 
Pop (wi) 
Expect. cases 
(wi*di/pi) 
Proportion     
(wi/sum(wi))  Variance  
25 to 29 0 28.5 0 2517100 0 0.095511843                     0 
30 to 34 0 37 0 2530200 0 0.096008925                    0 
35 to 39 0 68.5 0 2456100 0 0.093197186                   0 
40 to 44 0 164 0 2345400 0 0.088996653                   0 
45 to 49 0 183.5 0 2415200 0 0.091645228                   0 
50 to 54 1 116 0.00862069 2711300 23373.27586 0.102880799 7.79817E-07 
55 to 59 1 95.5 0.0104712 2653200 27782.19895 0.100676183  1.0997E-06 
60 to 64 0 48.5 0 2300100 0 0.087277736                   0 
65 to 69 0 22.5 0 1975700 0 0.074968316                   0 
70 to 79 0 9 0 4449500 0 0.168837132                    0 
 
2 773 0.00776197 26353800 140344.509 1 5.88095E-06 
   
0.00776197 Adj. Rate= 0.005325399 SE= 0.002425067 
 
pi : the number of PYs in age group i in the study population 
Ri: the cancer rate in age group i in the study population  
wi: the number of persons in age group i in the standard population 
 
Unadjusted Incidence Rate (per 100,000):   776.197   
Adjusted Incidence Rate (per 100,000):       532.540   95%CI (30-970) 
 
The ASIR of Anal Cancer among the study HIV-infected male population is 535.3/100,000 as 
compared to 1.5/100,000 in the Canadian general male population (PHAC, 1997-2006).  
The ASIR of Oropharyngeal Cancer among the study HIV-infected male population is 
532.5/100,000 as compared to 5.7/100,000 in the Canadian general male population (PHAC, 
1997-2006). 
 
Interpretation of these findings should be exercised with caution due to the short follow-up time 
for the exploration of the study outcomes. 
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CHAPTER 4 
 
DISCUSSION 
 
4.1 Summary of Key Findings 
Our key findings from this longitudinal cohort study included eight (3.3%) cases of cancer 
that were diagnosed among 245 male participants. Of them, six patients had anorectal cancer and 
2 males were diagnosed with oropharyngeal cancers. Thirty-one (11.8%) cases of precancerous 
lesions were confirmed among 263 study participants. Of them, two cases of vaginal/vulvar 
dysplasia belonged to the study females. Fifty HPV genotypes were observed among 263 HIV-
positive adults living in Atlantic Canada provinces. We have found that among those 50 HPV 
genotypes, seven were in significant relationship with the precancerous lesions (6, 11, 16, 18, 45, 
69 & 74) and two HR HPV genotypes HPV16 and HPV52 were significantly related to the 
incident cancer cases. We have also found a significant association between precancerous lesions 
and the following predictors: CD4 T cell count < 200 cells/mL, smoking, history of anogenital 
warts and genital herpes (HHV-2). An interaction between HPV 16 and HPV 74 was never 
reported prior to our study. Among the study patients who were HPV 74 positive,  those  with 
HPV 16 positive were 8.3 times more likely to have a  precancerous lesion than those who were 
HPV 16 negative (OR=8.3; p=0.0016). Furthermore, our findings showed that the risk of 
developing of an anal precancerous lesion increases by 10% with every one more count of HPV 
genotype in a single anal specimen (OR=1.1, p<0.0001).        
Our most significant and clinically important findings supported our main hypothesis about the 
higher incidence rates of HPV-associated cancers in HIV-infected people compared to the 
Canadian general population.                                                                                                         95 
 
 
The calculated Unadjusted Incidence Rates of anal cancer is 780/100,000 and oropharyngeal 
cancer is 776/100,000 in the study males. 
           The ASIR (95%CI) of anal cancer in our HIV-positive males, using the Canadian general 
male population as a reference population (Census and Statistics Canada, 2015), was 
535/100,000 (30-970) as compared to 1.5/100,000 in the Canadian general male population 
(PHAC, 1997-2006). Our 95% confidence interval is overlapping with the 95%CIs from two 
USA studies (Silverberg MJ et al in 2012; and Chaturvedi AK et al in 2009). The ASIR (95%CI) 
of anal SCC in HIV-infected MSM from the first study was 80.3 (42.7-151.1) and in HIV-
positive men was 26.7 (11.5-61.7). In the second study, they reported the ASIR (95%CI) of anal 
cancer being 34.6 (30.8-38.8) among their participants with AIDS (Table 1).  
The ASIR (95%CI) of oral cancer among our males was 533/100,000 (30-970) as compared to 
5.7/100,000 in the Canadian general male population (PHAC, 1997-2006).  
Even though our study was not designed to evaluate the burden of HPV-associated 
malignancy or to evaluate the feasibility of the anal cancer screening program for HIV-infected 
populations, we believe that our results contribute to quantifying the burden of anal cancer for 
HIV-positive males and their need for anal cancer screening program, early treatment of 
precancerous lesions and appropriate care. Immunosuppression is reported to be an important 
factor in the development of anal cancer, even though the association between anal cancer and 
HIV infection is difficult to confirm due to confounders (Van der Zee RP et al, 2013). Since 
HIV-positive MSM have 80-fold higher risk for anal cancer, an increase in the proportion of 
HIV-positive MSM in the population will contribute to a higher incidence of anal cancer in the 
general population (Gras L et al, 2007 and Van Sighem A et al, 2012). Diagnostic and 
therapeutic guidelines should be implemented for at-risk populations for anal dysplasia/anal 
cancer, such as HIV-positive men who have sex with men.                                                          96 
 
 
The implementation of the anal cancer screening program in Canada is timely important. Anal 
cancer is increasing in its incidence and is affecting more people across the world every year 
(http://analcancerfoundation.org/learn/anal-cancer/). The prevalence of the HIV-positive 
population in Canada is also rising and reached 75,750 in 2015. In addition, there is about 21% 
of Canadians with HIV who are unaware of their infection (PHAC, Fact Sheets, 2015). 
 
In this study, 50 HPV genotypes were detected. The number of the HPV infected 
participants increased by 4.3% from 82.0% at the baseline to 86.3% at the study end. The most 
frequently observed HPV genotype was HPV16 (102 (38.8%) cases), either as a single type in 
the specimen or in various combinations with other HPV genotypes. More than half of the study 
population (63.0%) had three and more HPV genotypes in their anal specimens. The number of 
patients infected with high-risk HPV genotypes increased by 17.1% from 45.9% at the baseline 
to 63.0% at the study completion.  We found that the most important HPV genotypes associated 
with the precancerous lesions and malignancy among Atlantic Canada PHAs were the following 
eight HPVs: 6, 11, 16, 18, 45, 52, 69 & 74. The findings from other studies support our findings.                                                                                                                                            
Evidence from a large international retrospective cross-sectional study from 38 countries, 
investigating the incidence of cervical cancer and related HPV genotypes in the general 
population for a period from 1949 to 2009, showed that the most frequently observed HPV 
genotypes were 16, 18, 31, 33, 35, 45, 52, & 58. Evidence from another comprehensive study in  
Spain demonstrated almost the same findings: eight most common HPV types in the 
development of cervical cancer were: 16, 18, 31, 33, 34, 45, 52 & 58 (de Sanjose et al, 2010).  
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The most recent study conducted by Mendez-Martinez and colleagues in 2014 (Mexico) was 
investigating the most prevalent HPV genotypes in the anal canal of HIV-positive MSM. They 
reported that the most frequently observed HPV genotype was 16 in various combination with 21 
other HPV types: 6, 11, 18, 26, 31, 33, 35, 44, 45, 51, 52, 53, 54, 56, 58, 59, 66, 68, 70, 74 & 82. 
They listed the combination of HPVs 16 and 74 which interaction we found to be important in 
their association with the precancerous lesions. Two HR HPV genotypes 16 and 52 were 
considered in our study to be individually important in their association with the development of 
anal cancers. Two HPV genotypes 69 and 74 were never reported as significant ones prior to our 
study. We cannot explain the uniqueness of our findings because our study was the first one 
among these types of investigation in Atlantic Canada HIV-positive adults.  
 
As we expected, the highest rates of both the precancerous lesions and cancers were observed 
in the older age category (21.4% and 4.9%, respectively). Prior to the study, we hypothesized 
that an increasing proportion of HIV-positive men in the older age group (60 years and older) 
would have an anal dysplasia or develop a cancer because of the contribution of the following 
factors:  (a) an absence of the effective anal cancer screening program in Atlantic Canada 
provinces (b) the increasing life span of HIV-positive people from HAART; their prolonged 
survival may be associated with increased risk of certain HPV-associated morbidity and cancer  
(c) the increasing number of people belonging to these risk groups. The age distribution of the 
pre- and malignant lesions in our study differs from other similar studies. The “EXPLORE” 
study was conducted to investigate the age-associated prevalence of HPV infection and anal 
cancer precursors in 1,409 HIV-negative MSM (Chin-Hong PV et al, 2004).  
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The overall prevalence of HPV infection was 57% and was similar across all age groups. 
Prevalence of both precancerous lesions LSILs and HSILs were also similar across age groups. 
The overall prevalence of any dysplasia was 32%, which was similar across age groups. The 
difference between our findings and findings from the “EXPLORE” study can be explained by 
the fact that we investigated HIV-positive males vs. HIV-negative MSM in Chin-Hong’s project.                                                                                                                                        
 
Our findings showed a significant effect of multiple HPV types (HPV polymorphism) on 
the risk of cancer precursors (OR=1.1, p<0.0001). From this, it is plausible to confirm findings 
from the previous studies that infection with multiple HPV genotypes may be a marker of 
persistent disease and of the progression of LSILs to HSILs. Both the presence of HPV infection 
and the number of HPV genotypes in the sample were important risk factors for precancerous 
lesions (Palefsky JM, et al, 1998; Kreuter A. & Wieland U., 2009; Palefsky JM et al, 2000).  
 
The underlying behavioral risk factors that were included in this analysis were: the 
number of sexual partners (both males and females), smoking status, self-reported history of 
STIs, and history of unprotected sex. We found a significant association between the 
precancerous lesions and patients’ smoking status (p=0.0070), history of anogenital warts and 
genital herpes (p=0.0020 & p=0.0071 respectively). Previous studies have also demonstrated that 
behavioral determinants were strongly associated with the risk of anal squamous intraepithelial 
lesions (ASILs) (Fairley CK et al, 1994; Burk RD, 1996; and Elam G et al, 2008).  
In 2004, Chin-Hong PV et al reported that patients who are knowledgeable about HPV and HIV 
can and do engage in high-risk sexual behaviors. 
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We found that the CD4 T cell count less than 200 cells/mL was associated with an 
increased risk of progression of HPV infection into precancerous lesions (p=0.0341). We did not 
find a significant association between high levels of plasma HIV RNA and the AINII/AINIII. 
Our findings partially confirmed the results from two previous Canadian studies. Mougin C. in 
2001 and Leece P. in 2010 investigated the correlations between HIV laboratory markers 
(CD4<200 cells/mL and high levels of plasma HIV RNA) and incidence of anal dysplasia, and 
found a strong relationship between these parameters. 
 
Most men (82.0%) in our study have never been screened for anal cytology abnormalities 
prior to the study. We compared our baseline data with the Canadian Human Immunodeficiency 
and Papillomavirus Research (HIPVIRG, 2011) baseline data. The sample size, median male 
age, percentage of smokers in the cohorts, percentage of patients who were taking antiretroviral 
therapy, as well as their baseline CD4 T cell counts were comparable between the cohorts. The 
HIPVIRG investigators aimed to establish a comprehensive understanding of the risk factors 
(age, smoking, initiation of anti-HIV treatment, CD4 cell count, and viral load level) for 
progression of AIN1 to AIN2 and AIN3 in HIV+ MSM. On entry to their study, 19% of patients 
had NILM (vs. 157 (57.1%) in our study); 50% had LSIL (vs. 36 (12.7%) in our study); AIN2 
was confirmed in 17% (vs. 5 (2.0%) in our males), and 13% of their males had AIN3 (vs. 4 
(1.7%) among our males). The incidence of AIN2/AIN3 in their HIV-positive male cohort was                                                                                                                                                                                                                                                                                                          
23% after two years of observation and 37% after three years of observation. In our study, the 
incidence of AIN2/AIN3 among the study males was ten times less at 3.7% (9/245) at the end of 
the three years of follow-ups. The discrepancies in the results can be explained by (1) 
Significantly higher number of NILM reports among our male population at the enrollment time  
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(2) The homogenous MSM population in HIPVIRG versus our male sample which included 
proportions of MSM, MSW and MSMW.                                                                          
 
In our study, we detected six ASC-US and one LSIL oropharyngeal lesions. These patients 
were referred to ENT specialists for further investigation and observation. We did not receive 
histopathology reports regarding these patients’ oral lesions. Therefore, we assumed that by 
specialist’s opinion their lesions did not require a biopsy. Two male patients diagnosed with 
tongue and throat cancers had NILM in their cytology reports and were never referred to ENT 
specialists at that time. They were referred to specialists later on because of their clinical signs 
and symptoms. Both oropharyngeal cancers were associated with HPV 16. The other HPV 
genotypes detected in these patients’ oropharyngeal specimens were: 32, 35, 45, 58, 70 & 72.  
Men who have sex with men have a higher risk of developing oral HPV infection. A 2009 study 
conducted by D’Souza et al found that oral HPV acquisition is more positively associated with 
the number of recent oral sex and open mouth kissing partners than with the number of vaginal 
sex partners. Additionally, the prevalence of oral condylomas (large warts) has increased 
dramatically since the introduction of highly active anti-retroviral therapy (HAART) (Rabkin 
CS, 1998; Bower M et al, 2004; and Palefsky JM et al, 2001), which may be due to immune 
reconstitution (BCCA Vancouver Centre). HPV infection not only causes oral condylomas but is 
also strongly associated with oropharyngeal cancers and other oral diseases (Canadas MP et al,                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            
2004; Gillison ML et al, 2008). The incidence of HPV-associated carcinomas of the oropharynx 
substantially increased from 1973 to 2004 (p<0.001), most likely because of a shift in sexual 
behavior, particularly oral sex in young males (Kreuter A. & Wieland U., 2009).  
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4.2 Policy Implications 
The CFA (Centre for AIDS Information & Advocacy) advocates both locally and nationally 
for better treatments and better access to care for persons living with HIV/AIDS. No direct 
evidence exists to support the effectiveness of an anal Pap test screening program to reduce anal 
cancer mortality and morbidity (Goldie SJ et al, 1999). There are however, strong parallels 
between cervical pap testing and cervical cancer (D’Souza G et al, 2009). Sexually transmitted 
HPV viral infection is currently an acknowledged common causative agent for both anal and 
cervical cancers. Recent anal cancer rates in high-risk populations (HIV+ MSM) exceed those of 
cervical cancer before the implementation of the cervical cancer screening program (77.8-
134/100,000 vs. 40/100,000, respectively) (Machalek DA, et al, 2012). Screening tests for these 
populations may be effective in reducing incidence, morbidity and mortality rates of anal cancer, 
as has been documented with cervical cancer. The implementation of cervical cancer screening 
resulted in a drop in cervical cancer rates from ~40/100,000 to ~8/100,000. Based on the success 
of the Pap test for cervical cancer screening, use of a similar Pap test for detection and early 
eradication of anal cancer precursors could potentially prevent their progression to anal cancer. 
Anal cancer screening may be cost-effective in HIV-infected and HIV-uninfected MSM (Goldie 
SJ et al, 1999 & 2000; Katz KA et al, 2009; RITA Report, 2013).                                                                                                                                                                                                                                                                                             
The author’s opinion is supported by the findings from this study and from previously-conducted 
studies. In their qualitative study in 2010, Reed AC et al. found that 83% of gay and bisexual 
men were willing to accept free screening for anal cancer, leading to the conclusion that the 
screening’s cost is a major barrier. Ours was a unique prospective cohort study investigating the 
prevalence of HPV genotypes in HIV-positive adults in Atlantic Canada provinces and their 
association with the precancerous lesions and newly diagnosed malignancy.  
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Our findings might be found important in the context of clinical management and prevention of 
HPV-associated dysplasia and cancers in Canadians living with HIV/AIDS. 
 
4.3 The Study Limitations 
We acknowledge the study’s limitations and provide their detailed description.                                                                                                                         
The 26-item Patient Questionnaire (PQ) was administered to all participants at the enrollment 
time only. We might have drawn more conclusions about the association between patient’s 
behavior and incidence of primary outcome if the PQ was updated by patients at each year 
during the follow-up period 
There was a probability of systematic bias such as information and particularly recall bias 
regarding the information provided in the self-reported 26-item PQ, such as patients’ history of 
STIs, number of sexual partners during the year, previously performed anal Pap test, and others. 
There was also a probability of the sample bias taking into the consideration that all our 
participants were volunteers.                                                                                                                                                  
The information in the 12-item Baseline and 9-item Clinic Follow-up Questionnaires 
included snap-shot annual values of CD4 T cell count and HIV RNA load. We never had an 
opportunity to analyze these measurements’ means, maximum and minimum values during the 
year of observation. The snap-shot nature of the measurements has definitely limited the 
outcome analysis. 
Our male participants were not asked to self-identify as MSM, MSMW or MSW in the 26-
item PQ, even though the data in majority of questionnaires indicated them as MSM. This data 
would perhaps allow us to draw stronger conclusions about the prevalence of HPV genotypes 
and their association with patients’ sexual behavior by comparing HIV-positive homosexual men 
with HIV-positive heterosexual men.                                                                                          103 
 
 
Another possible limitation of the study was the fact that we had one cytopathologist. There 
was a fair chance of bias in the results reading and their reports. However, any potential under- 
or over-diagnosis of squamous intraepithelial lesions (SILs) would probably affect only the 
incidence estimates, and not the estimates of associations with the potential risk factors. Ideally, 
this study needed to follow all cases out to histology with biopsy to confirm the detected ones 
and discover potentially undetected cytologic abnormalities.  
The PCR assay (Luminex) used in the study for HPV DNA detection had limited sensitivity 
level. We might assume that a certain proportion of dysplasia was not detected to begin with. It 
should be considered that detection of HPV DNA usually indicates current infection, while not 
totally excluding surface contamination. Similarly, failure to detect HPV DNA does not exclude 
HPV infection as low-level infections or mere sampling errors. 
 
4.4 Future Research 
     Although this study answered some important questions, other questions related to the subject 
remain unanswered. One of the questions that need to be answered is the prevalence of HR HPV 
genotypes in HIV-positive MSM living in Atlantic Canada provinces and their association with 
anal/oropharyngeal dysplasia and cancer. This question became more focused and feasible 
because of our findings. We also suggest further investigation clarifying the age influence on the 
incidence and prevalence of HPV-related precursor lesions observed in this study.  Another 
promising avenue of research would be to continue to investigate the feasibility of anal cancer 
screening program for HIV-infected adults living in Atlantic region of Canada. More research is 
needed to better understand the complex relationship between independent predictors and 
incident cancers/precursor lesions, increased health risk and its association with health service 
utilization.                                                                                                                                    104 
 
 
CHAPTER 5 
 
CONCLUSIONS 
 
The main outcome of this study was the incidence of HPV related cancers in HIV-
positive adults living in Atlantic region of Canada. HIV-infected individuals are living longer 
and therefore may have the opportunity to acquire more slowly developing HPV-associated 
malignancies. Based on the data analysis and study findings, the following conclusions have 
been reached.  
The factors predictive of progression of HPV infection to high-grade anal intraepithelial 
neoplasia (AIN), the immediate precursor of anal cancer in HIV-positive males are (1) HIV 
seropositivity per se (2) Advanced age (3) Persistence of anal HPV infection with one or more of 
the seven genotypes 6, 11, 16, 18, 45, 69 & 74 (4) Presence of multiple (≥3) HPV genotypes in a 
single specimen (5) Blood CD4 T cell count less than 200 cells/mL (6) Smoking and (7) History 
of anogenital warts and genital herpes. The highest rates of both the precancerous lesions and 
cancers are found to be among the study PHAs of 60 years of age and older (21.4% and 4.9%, 
respectively). Two high-risk HPV genotypes 16 & 52 are individually associated with the 
development of cancer. The ASIRs of anal cancer is 535/100,000 and of oral cancer is 
533/100,000. Based on the findings from this study, we developed recommendations that need to 
be addressed to our knowledge users, policy makers and stakeholders such as Atlantic Canada 
Health Care Authorities, medical communities, and people living with HIV/AIDS.  
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5.1 Individual-Based Approach and Intervention 
A screening approach is not yet established as the standard of care in HIV clinics 
(Palefsky JM, 2013 [RITA]). Our recommendations for HIV-infected individuals who practice              
receptive anal intercourse include use of protection and annual anal Pap and HPV genotyping 
tests.  The Human Papillomavirus test can be the dominant screening method for people living 
with HIV/AIDS until the implementation of the anal cancer screening program.                          
The combination of DRE, anal HPV and Pap test screening would be beneficial for these 
populations (Palefsky JM et al, 2011; Franco E., 2016).                                                                                                                                                                                                                                                                                                                                            
We also believe that there is a need for medical communities in Canada, and particularly 
in Atlantic Canada, to start performing optimal early screening and treatment protocols for these 
populations, something that has not yet been coordinated. HPV is a common infection and 
certain interventions might affect the incidence of HPV-associated cancers. Many clinicians are 
unfamiliar with the procedure and the purpose of anal Pap testing. Appropriate triage and referral 
for care of anal cytologic abnormalities should ideally be clearly-defined before implementation 
of anal Pap test screening (Ostoski RA & Kell CS, 2011). Clinicians should be aware of the risk 
factors for HPV, which could prove useful in identifying patients at high risk for HPV-associated 
cancers, and modifying patient care to minimize this risk. The investigators believe that patients 
with a low nadir CD4 cell count might especially benefit from screening for precancerous 
lesions. In addition, “typing could also be useful as an adjunct to cytological examination in 
primary screening” (De Pokomandy A. et al, 2011; RITA Report, 2013). Just as it has been 
previously done with cervical cancer, we believe that widespread practice of effective protocols 
for early detection and early intervention of HPV-related anal dysplasia and cancer might help 
prevent many HIV-positive individuals from ever developing anal cancer.  
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5.2 Challenges and Opportunities to the Individual-Based Approach 
One challenge to the individual-based approach is that it is labor intensive and requires 
coordinated input from many healthcare professionals. A second challenge to this approach is the 
requirement of increased collaboration between disciplines and the need to establish a team of 
multidisciplinary professionals in order to deliver the services recommended. The recommended 
screening and management options for HIV-positive adults may be associated with increased 
costs in the short-term due to the resources required (e.g., training, equipment, financial support). 
The hope however is that in the long-term, this approach will be more cost-effective and the 
health of HIV-positive individuals will improve as the health effects of HPV-associated 
precancerous lesions and cancers are treated early, managed effectively, and potentially 
minimized. 
Our study was the first study that investigated prevalence of HPV-associated precursor 
lesions and incidence of cancers in HIV-positive adults living in Atlantic Canada provinces. It 
was the first study that reported the prevalence of HR HPV genotypes and examined association 
of those HPVs with the dysplasia and cancers. We also found a unique association of HPV69 & 
HPV74 with the 29 precancerous lesions among the 245 HIV-positive study males. The 
interaction between HPV74 and HPV16 in their association with these precancerous lesions was 
also a unique finding as compare to other studies. The impact of the study findings are their 
contribution to quantifying the burden of HPV-associated anal cancer for HIV-infected males 
and their need for an anal cancer screening program, early treatment of precancerous lesions, and 
appropriate care. The high incidence of anal cancer among HIV-positive individuals must not be 
ignored, since it may be preventable (Palefsky JM. et al., 2013). The evidence from this and 
other studies strongly suggest continuing research in this direction to enhance the dissemination 
and implementation of research findings into clinical management and policy decisions.       107                                                                                          
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APPENDIX A: Study Ad Poster 
   
 
HIV-HPV STUDY  
If you are HIV-positive male or female & live in Atlantic Canada, we 
are seeking your participation in an  
Atlantic Canada HIV-HPV Study 
For more information or to enrol in this study, please contact your 
HIV clinic nurse or physician 
Or, you may contact the study principal investigator:  
Dr. Gerry Mugford 
 Associate Professor of Medicine and Psychiatry 
Faculty of Medicine, Memorial University of Newfoundland, St. John’s 
Telephone: 709 777 7390 
 Fax: 709 777 7877 
Email: gmugford@mun.ca; Pager: 709 570-9090; Secretary: 709 777-7346 
          
 
 
 
 
 
 
 
 
 
 
 
 
109 
 
 
APPENDIX B: Consent Form 
110 
 
 
111 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
112 
 
 
 
 
 
113 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
114 
 
 
APPENDIX C: 26-item Patient Baseline Questionnaire 
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APPENDIX D: 12-item Clinic Baseline Questionnaire 
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APPENDIX E: 9-item Follow-up Clinic Questionnaire 
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APPENDIX F: Patient’s Enrolment Card 
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APPENDIX G: NYS DOH Specimen Collection Guidelines 
 
Technique: (NYS Guidelines recommendations on anal pap smears, NYS DOH AIDS Institute’s 
HIV quality-related website - http://hivguidelines.org/Content.aspx). 
  
      There is no preparation necessary before obtaining anal cytology. If the digital rectal 
examination is performed in conjunction with anal cytology and/or HRA, the cytology must be 
obtained first, before lubrication is introduced into the anal canal. Patients should not have 
received an enema or engaged in receptive anal sex within 24 hours before sampling because 
these activities can adversely affect specimen quality. 
  
      The standard technique used in obtaining anal cytology is as follows: a Dacron swab (a 
cotton swab will not yield accurate results) is moistened with sterile or non-sterile water. The 
anus is spread with the index and thumb of the non-dominant hand so that the anoderm pouts out. 
The swab is then gently inserted into the anal canal as far as it will go, until it hits the wall of the 
rectum. If the swab does not go in easily, the angle of insertion should be adjusted. The presence 
of external hemorrhoids may cause resistance; in this case, different insertion points should be 
tried until the anal canal is easily accessed. The swab must be inserted above the 
squamocolumnar transition zone, which is approximately 2 cm (1 inch) from the anal verge. 
  
      The swab is then slowly moved in and out without completely withdrawing it, while rotating 
it in a spiral motion and applying mild pressure to the anal wall. After several rotations, the swab 
should be withdrawn and immediately immersed in methanol-based preservative-transport 
solution. Feces or traces of blood on the swab will not affect the result. The swab should be 
agitated in the solution for 60 seconds to transfer cells from the swab to the medium. 
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